image_name stringlengths 68 68 | type stringclasses 2
values | gt_table stringlengths 116 12.6k | table_fragment_1 stringlengths 43 8.42k | table_fragment_2 stringlengths 39 8.21k |
|---|---|---|---|---|
df3630f9788fa5702a70626f7b4a50740154bc54c191e50d952c345b31a0db20.png | simple | <table><tr><td>First author</td><td>Year</td><td>Skin condition</td></tr><tr><td>Praveenkumar et al. [29]</td><td>2016</td><td>Psoriasis</td></tr><tr><td>Kokpol et al. [30]</td><td>2014</td><td>Psoriasis</td></tr><tr><td>Henseler et al. [31]</td><td>1995</td><td>Psoriasis</td></tr><tr><td>Owczarczyk-Saczonek et al. [34... | <table><tr><td>First author</td><td>Year</td><td>Skin condition</td></tr><tr><td>Praveenkumar et al. [29]</td><td>2016</td><td>Psoriasis</td></tr><tr><td>Kokpol et al. [30]</td><td>2014</td><td>Psoriasis</td></tr><tr><td>Henseler et al. [31]</td><td>1995</td><td>Psoriasis</td></tr><tr><td>Owczarczyk-Saczonek et al. [34... | <table><tr><td>Arias-Santiago et al. [65]</td><td>2011</td><td>Lichen planus</td></tr><tr><td>Lee et al. [68]</td><td>2017</td><td>Atopic dermatitis</td></tr><tr><td>Ambiel et al. [71]</td><td>2014</td><td>Pemphigus</td></tr><tr><td>Saylam Kurtipek et al. [83]</td><td>2015</td><td>Holoderma</td></tr><tr><td>Wali et al.... |
6e9bfacd730265b2a009132e6662ec63339bcd81bb45fdf418bedfe660d57a50.png | simple | <table><tr><td>MIGS ID</td><td>Property</td><td>Term</td><td>Evidence code<sup>a</sup></td></tr><tr><td></td><td></td><td>Domain <i>Bacteria</i></td><td>TAS [13]</td></tr><tr><td></td><td></td><td>Phylum <i>Bacteroidetes</i></td><td>TAS [14,15]</td></tr><tr><td></td><td></td><td>Class <i>Bacteroidia</i></td><td>TAS [14... | <table><tr><td>MIGS ID</td><td>Property</td><td>Term</td><td>Evidence codea</td></tr><tr><td></td><td></td><td>Domain Bacteria</td><td>TAS [13]</td></tr><tr><td></td><td></td><td>Phylum Bacteroidetes</td><td>TAS [14,15]</td></tr><tr><td></td><td></td><td>Class Bacteroidia</td><td>TAS [14,16]</td></tr><tr><td></td><td>C... | <table><tr><td></td><td>Energy source</td><td>Unknown</td><td>NAS</td></tr><tr><td>MIGS-6</td><td>Habitat</td><td>Human gut</td><td>IDA</td></tr><tr><td>MIGS-15</td><td>Biotic relationship</td><td>Free living</td><td>IDA</td></tr><tr><td>MIGS-14</td><td>PathogenicityBiosafety levelIsolation</td><td>Unknown2Human feces<... |
0d0bc9de6c6c29ae5507a5362d45889429184a8828acde20cc00d8244c7b007d.png | complex | <table><tr><td> </td><td>Correct reactions</td><td>Correct</td></tr><tr><td> </td><td>(ignoring enzyme)</td><td>(including enzyme)</td></tr><tr><td colspan="3"><i>Pantothenate and coenzyme A biosynthesis pathway</i></td></tr><tr><td>Recall(P) (%)</td><td>78 (7/9)</td><td>56 (5/9)</td></tr><tr><td>Precision (%)</td><td>... | <table><tr><td></td><td>Correct reactions</td><td>Correct</td></tr><tr><td></td><td>(ignoring enzyme)</td><td>(including enzyme)</td></tr><tr><td colspan="3">Pantothenate and coenzyme A biosynthesis pathway</td></tr><tr><td>Recall(P) (%)</td><td>78 (7/9)</td><td>56 (5/9)</td></tr><tr><td>Precision (%)</td><td>59 (24/41... | <table><tr><td></td><td>Correct reactions</td><td>Correct</td></tr><tr><td></td><td>(ignoring enzyme)</td><td>(including enzyme)</td></tr><tr><td>all(P) (%)</td><td>(2/7)</td><td>2/7)</td></tr><tr><td>Precision (%)</td><td>30 (11/37)</td><td>14 (5/37)</td></tr></table> |
88df28ea23405e43bd18e8d4352dd8b2eaa24079d0e7c8c31b0f4827be5034ed.png | complex | <table><tr><td rowspan="2">Prognosis</td><td rowspan="2">Wald</td><td rowspan="2"><i>P</i></td><td rowspan="2">Exp(B)</td><td colspan="2">95% CI for Exp(B)</td></tr><tr><td>Lower</td><td>Upper</td></tr><tr><td colspan="6">OS</td></tr><tr><td> Age(year) ≥50 vs.<50</td><td>1.577</td><td>0.215</td><td>1.643</td><... | <table><tr><td rowspan="2">Prognosis</td><td rowspan="2">Wald</td><td rowspan="2">P</td><td rowspan="2">Exp(B)</td><td colspan="2">95% CI for Exp(B)</td></tr><tr><td>Lower</td><td>Upper</td></tr><tr><td colspan="6"></td></tr></table> | <table><tr><td colspan="6">OS</td></tr><tr><td>Age(year) ≥50 vs.<50</td><td>1.577</td><td>0.215</td><td>1.643</td><td>0.788</td><td>3.319</td></tr><tr><td>Gender Female vs. Male</td><td>3.298</td><td>0.081</td><td>2.506</td><td>0.907</td><td>6.387</td></tr><tr><td>Histological type U vs. D</td><td>0.441</td><td>0.526</... |
0f5091127833f44ca93627013095fc334613017b7618ad4b4dc901ee9aed6717.png | simple | <table><tr><td>Year</td><td>Zonal Population*</td><td>New PTB+ cases Reported (n = 8558)</td><td>Case Notification/ 10<sup>5 </sup>persons/year</td><td>Proportion of estimated PTB+ incident cases notified, %**</td></tr><tr><td>1994</td><td>1004000</td><td>512</td><td>49</td><td>45.2</td></tr><tr><td>1995</td><td>107016... | <table><tr><td>Year</td><td>Zonal Population*</td><td>New PTB+ cases Reported (n = 8558)</td><td>Case Notification/ 105 persons/year</td><td>Proportion of estimated PTB+ incident cases notified, %**</td></tr><tr><td>1994</td><td>1004000</td><td>512</td><td>49</td><td>45.2</td></tr><tr><td>1995</td><td>1070160</td><td>1... | <table><tr><td>1997</td><td>1133129</td><td>946</td><td>84</td><td>76.6</td></tr><tr><td>1998</td><td>1165990</td><td>1277</td><td>110</td><td>100.5</td></tr><tr><td>1999</td><td>1199804</td><td>1510</td><td>126</td><td>115.5</td></tr><tr><td>2000</td><td>1234598</td><td>1267</td><td>103</td><td>94.2</td></tr><tr><td>2... |
ba6ce94cca53afd61e5255004343c6fc9b0c8923923d61d5057e7c9eb315a8dd.png | complex | <table><tr><td rowspan="3"></td><td colspan="2">Intervention (n=5297)</td><td colspan="2">Control (n=5246)</td><td rowspan="2">Incidence rate ratio (95% CI)</td><td rowspan="2">p value</td></tr><tr><td>Number of events</td><td>Incidence rate (cases per 100 child-years, 95% CI)</td><td>Number of events</td><td>Incidence... | <table><tr><td rowspan="3"></td><td colspan="2">Intervention (n=5297)</td><td colspan="2">Control (n=5246)</td><td rowspan="2">Incidence rate ratio (95% CI)</td><td rowspan="2">p value</td></tr><tr><td>Number of events</td><td>Incidence rate (cases per 100 child-years, 95% CI)</td><td>Number of events</td><td>Incidence... | <table><tr><td rowspan="3"></td><td colspan="2">Intervention (n=5297)</td><td colspan="2">Control (n=5246)</td><td rowspan="2">Incidence rate ratio (95% CI)</td><td rowspan="2">p value</td></tr><tr><td>Number of events</td><td>Incidence rate (cases per 100 child-years, 95% CI)</td><td>Number of events</td><td>Incidence... |
458232217823a6db4067442756c5dc85ccd69749b8029868d5f80b6e0dd01371.png | simple | <table><tr><td>Folates</td><td>Methionine cycle</td><td>Transsulfuration</td><td>Other</td></tr><tr><td>THF = 4.61</td><td>Met = 49.2</td><td>Cysta = 36.9</td><td>Ser = 563</td></tr><tr><td>510CH = 0.28</td><td>SAM = 81.1</td><td>Cys = 195</td><td>Gly = 924</td></tr><tr><td>510CH2 = 0.51</td><td>SAH = 19.1</td><td>GluC... | <table><tr><td>Folates</td><td>Methionine cycle</td><td>Transsulfuration</td><td>Other</td></tr></table> | <table><tr><td>THF = 4.61</td><td>Met = 49.2</td><td>Cysta = 36.9</td><td>Ser = 563</td></tr><tr><td>510CH = 0.28</td><td>SAM = 81.1</td><td>Cys = 195</td><td>Gly = 924</td></tr><tr><td>510CH2 = 0.51</td><td>SAH = 19.1</td><td>GluCys = 9.8</td><td>Sarc = 9.16</td></tr><tr><td>10fTHF = 3.41</td><td>Hcy = 1.12</td><td>GS... |
b8505365dcd6616aad320fa968c7e4b472e0bf87654c47eeedab4c06969847d5.png | complex | <table><tr><td>Physical symptoms</td><td colspan="4">GSF group</td><td colspan="4">Non-GSF group</td><td> </td></tr><tr><td>Subscale and item</td><td>Very much</td><td>Quite a bit</td><td>A little bit</td><td>Not at all</td><td>Very much</td><td>Quite a bit</td><td>A little bit</td><td>Not at all</td><td>Missing</td></... | <table><tr><td>Physical symptoms</td><td colspan="4">GSF group</td><td colspan="4">Non-GSF group</td></tr><tr><td>Subscale and item</td><td>Very much</td><td>Quite a bit</td><td>A little bit</td><td>Not at all</td><td>Very much</td><td>Quite a bit</td><td>A little bit</td><td>Not at all</td></tr><tr><td></td><td>n(%)</... | <table><tr><td></td></tr><tr><td>Missing</td></tr><tr><td>n(%)</td></tr><tr><td>19 (3.7)</td></tr><tr><td>26 (5.1)</td></tr><tr><td>27 (5.3)</td></tr><tr><td>21 (4.1)</td></tr><tr><td>30 (5.8)</td></tr><tr><td>17 (3.3)</td></tr><tr><td>27 (5.3)</td></tr><tr><td>22 (4.3)</td></tr><tr><td>28 (5.4)</td></tr><tr><td>13 (2.... |
05feba05bb227e047605f3b26b40651b7461c5d710aaf9650732123fdbc220a1.png | complex | <table><tr><td>Experimental phase</td><td>Correlation</td><td>Brain regions</td><td>x</td><td>y</td><td>z</td><td>Cluster size</td><td>t value</td><td><i>p</i> value FWE</td></tr><tr><td rowspan="7">Fear conditioning</td><td rowspan="5">Positive</td><td>Posterior cingulate cortex</td><td>12</td><td>−34</td><td>46... | <table><tr><td>Experimental phase</td><td>Correlation</td><td>Brain regions</td><td>x</td><td>y</td><td>z</td><td>Cluster size</td><td>t value</td></tr><tr><td rowspan="7">Fear conditioning</td><td rowspan="5">Positive</td><td>Posterior cingulate cortex</td><td>12</td><td>−34</td><td>46</td><td>70</td><td>3.10</td></tr... | <table><tr><td>p value FWE</td></tr><tr><td>0.033</td></tr><tr><td>0.034</td></tr><tr><td>0.037</td></tr><tr><td>0.039</td></tr><tr><td>0.051</td></tr><tr><td>0.038</td></tr><tr><td>0.039</td></tr><tr><td>0.015</td></tr><tr><td>0.040</td></tr><tr><td>0.011</td></tr><tr><td>0.028</td></tr><tr><td>0.024</td></tr><tr><td>... |
801fe1688b500378cb8341cf0b13ed479c9d1a602cd5099184a82d62816ca4fb.png | complex | <table><tr><td> </td><td colspan="2">ANXA1-SER</td><td> </td><td colspan="2">ANXA1-TYR</td><td> </td></tr><tr><td> </td><td>HPV+</td><td>HPV-</td><td>Controls</td><td>HPV+</td><td>HPV-</td><td>Controls</td></tr><tr><td>Cancer</td><td>13.5 ± 1.6</td><td>14.6 ± 0.4</td><td>-</td><td>15.3 ± 0.6**</td><td>13... | <table><tr><td></td><td colspan="2">ANXA1-SER</td><td></td></tr><tr><td></td><td>HPV+</td><td>HPV-</td><td>Controls</td></tr><tr><td>Cancer</td><td>13.5 ± 1.6</td><td>14.6 ± 0.4</td><td>-</td></tr><tr><td>Epithelium</td><td>23.2 ± 1.7*</td><td>16.0 ± 1.0</td><td>15.3 ± 0.3</td></tr></table> | <table><tr><td colspan="2">ANXA1-TYR</td><td></td></tr><tr><td>HPV+</td><td>HPV-</td><td>Controls</td></tr><tr><td>15.3 ± 0.6**</td><td>13.6 ± 1.6*</td><td>-</td></tr><tr><td>22.2 ± 0.7</td><td>18.5 ± 1.5</td><td>26.7 ± 0.9</td></tr></table> |
884c7598b284831c458f06c075822de9857cd2c245c98bf00e13e004d0e8010e.png | complex | <table><tr><td>Variations</td><td></td><td>1<sup>st</sup> Day</td><td>2<sup>nd</sup> Day</td><td>3<sup>rd</sup> Day </td><td>P value</td></tr><tr><td rowspan="2">Number of bolusesrequired</td><td>Group B</td><td>31.47±24.39</td><td>24.07±20.25</td><td>19.20±14.59</td><td rowspan="2">0.084</td></tr><tr><t... | <table><tr><td>Variations</td><td></td><td>1st Day</td><td>2nd Day</td><td>3rd Day</td><td>P value</td></tr><tr><td rowspan="2">Number of bolusesrequired</td><td>Group B</td><td>31.47±24.39</td><td>24.07±20.25</td><td>19.20±14.59</td><td rowspan="2">0.084</td></tr><tr><td>Group L</td><td>38.87±28.27</td><td>21.13±16.82... | <table><tr><td>Number of bolusesdelivered</td><td>Group L</td><td>16.37±8.39</td><td>9.70±5.42</td><td>8.50±4.20</td><td>0.348</td></tr><tr><td rowspan="2">Total Consumption(ml)</td><td>Group B</td><td>79.17±33.45</td><td>49.67±23.81</td><td>44.67±19.78</td><td rowspan="2">0.371</td></tr><tr><td>Group L</td><td>81.67±4... |
4079a9ac9a773f44129f423cb6c776a35d8986edf46a3ef19853543bc82e7179.png | complex | <table><tr><td>Components</td><td>Mean IOP (±SD)</td><td>P Value</td><td>Mean CCT (±SD)</td><td>P Value</td></tr><tr><td colspan="5">Abdominal Obesity</td></tr><tr><td>Yes</td><td>26.23±4.17</td><td>0.126</td><td>591.12±56.15</td><td>0.317</td></tr><tr><td>No </td><td>25.34±3.76</td><td> </td><... | <table><tr><td>Components</td><td>Mean IOP (±SD)</td><td>P Value</td><td>Mean CCT (±SD)</td><td>P Value</td></tr><tr><td colspan="5">Abdominal Obesity</td></tr><tr><td>Yes</td><td>26.23±4.17</td><td>0.126</td><td>591.12±56.15</td><td>0.317</td></tr><tr><td>No</td><td>25.34±3.76</td><td></td><td>596.34±91.77</td><td></t... | <table><tr><td>No</td><td>23.74±3.34</td><td></td><td>597.52±73.73</td><td></td></tr></table> |
baa49a5311ba1cb99c1d125d90f87bcc0100a0efff00f382f0eb2127e9b7d9c8.png | simple | <table><tr><td>Reference</td><td>Measurement of PAH-RPF/true RPF (<i>n</i>/<i>n</i>)</td><td>PAH-RPF (ml/min)</td><td>True RPF (ml/min)</td></tr><tr><td>[17]</td><td>6 (0)</td><td>-</td><td>690</td></tr><tr><td>[18]</td><td>40 (11)</td><td>475</td><td>1116</td></tr><tr><td>[19]</td><td>22 (6)</td><td>474</td><td>1238</... | <table><tr><td>Reference</td><td>Measurement of PAH-RPF/true RPF (n/n)</td><td>PAH-RPF (ml/min)</td><td>True RPF (ml/min)</td></tr><tr><td>[17]</td><td>6 (0)</td><td>-</td><td>690</td></tr><tr><td>[18]</td><td>40 (11)</td><td>475</td><td>1116</td></tr></table> | <table><tr><td>[19]</td><td>22 (6)</td><td>474</td><td>1238</td></tr></table> |
0a4ad1a9056f7b176cf2ea7fe8eb0917b9be54c51f13024f6daa7e8e677d95f5.png | simple | <table><tr><td>SNP</td><td>MAF (% [<i>n</i>/<i>N</i>])</td><td>OR (95% CI)</td><td><i>P</i></td></tr><tr><td>rs600144</td><td></td><td></td><td></td></tr><tr><td> Cases</td><td>25.9 (850/3278)</td><td>0.96 (0.9 to 1.1)</td><td>NS</td></tr><tr><td> Controls</td><td>26.8 (857/3202)</td><td></td><td></td></tr><tr><td>rs11... | <table><tr><td>SNP</td><td>MAF (% [n/N])</td><td>OR (95% CI)</td><td>P</td></tr><tr><td>rs600144</td><td></td><td></td><td></td></tr><tr><td>Cases</td><td>25.9 (850/3278)</td><td>0.96 (0.9 to 1.1)</td><td>NS</td></tr><tr><td>Controls</td><td>26.8 (857/3202)</td><td></td><td></td></tr><tr><td>rs11970361</td><td></td><td... | <table><tr><td>Controls</td><td>10.1 (328/3238)</td><td></td><td></td></tr><tr><td>rs582757</td><td></td><td></td><td></td></tr><tr><td>Cases</td><td>24.8 (816/3286)</td><td>0.89 (0.8 to 0.99)</td><td>0.041</td></tr><tr><td>Controls</td><td>27.0 (871/3220)</td><td></td><td></td></tr><tr><td>rs17780429</td><td></td><td>... |
317ae5f6077fa3828d0080382e0125a678cabee0ab909c72fc73826c4ff3c14f.png | simple | <table><tr><td></td><td>accepted marine species in WORMS</td><td>18S V9 OTUs in plankton<sup>a</sup></td></tr><tr><td>Acanthocephala</td><td>468</td><td>0</td></tr><tr><td>Annelida</td><td>12 862</td><td>404 (48)</td></tr><tr><td>Arthropoda</td><td>57 871</td><td>9497 (205)</td></tr><tr><td>Brachiopoda</td><td>396</td>... | <table><tr><td></td><td>accepted marine species in WORMS</td><td>18S V9 OTUs in planktona</td></tr><tr><td>Acanthocephala</td><td>468</td><td>0</td></tr><tr><td>Annelida</td><td>12 862</td><td>404 (48)</td></tr><tr><td>Arthropoda</td><td>57 871</td><td>9497 (205)</td></tr><tr><td>Brachiopoda</td><td>396</td><td>8 (4)</... | <table><tr><td>Echinodermata</td><td>7252</td><td>74 (19)</td></tr><tr><td>Entoprocta</td><td>180</td><td>12</td></tr><tr><td>Gastrotricha</td><td>497</td><td>2</td></tr><tr><td>Gnathostomulida</td><td>98</td><td>0</td></tr><tr><td>Hemichordata</td><td>130</td><td>12 (3)</td></tr><tr><td>Mollusca</td><td>45 219</td><td... |
c6fcb27ef2020c9eaaab7056b2b755a00ca4d33e23a7371d480b443571e665d2.png | complex | <table><tr><td></td><td>CON</td><td>HSD2BKO</td></tr><tr><td>Adrenal size: body weight (adult)</td><td>5.9 ± 0.9 × 10<sup>−4</sup> (15)</td><td>4.9 ± 0.9 × 10<sup>−4</sup> (18)</td></tr><tr><td colspan="3">

</td></tr><tr><td colspan="3">Brain gene expression (<i>n</i> = 5... | <table><tr><td></td><td>CON</td><td>HSD2BKO</td></tr><tr><td>Adrenal size: body weight (adult)</td><td>5.9 ± 0.9 × 10−4 (15)</td><td>4.9 ± 0.9 × 10−4 (18)</td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3">Brain gene expression (n = 5–8)</td></tr><tr><td>Crh (E15.5; PVN)(ROD)</td><td>0.336 ± 0.01</td><td>0.320 ... | <table><tr><td></td><td>CON</td><td>HSD2BKO</td></tr><tr><td>Hsd11b1 (E17.5; norm to HPRT)</td><td>0.188 ± 0.028</td><td>0.148 ± 0.022</td></tr><tr><td colspan="3"></td></tr><tr><td colspan="3">Plasma corticosterone (nmol/l)</td></tr><tr><td>Fetal (E17.5)</td><td>31.2 ± 2.1</td><td>28.1 ± 2.0</td></tr><tr><td colspan="... |
7f0741322e631626567490dd7a75914c89ac6054c5612e7db1f01f4ed0599bde.png | simple | <table><tr><td>Level of lesion</td><td>Number of patients</td><td>Percentage</td></tr><tr><td>Thoracic</td><td>3</td><td>3.49</td></tr><tr><td>Thoracolumbar</td><td>6</td><td>6.98</td></tr><tr><td>Lumbar</td><td>23</td><td>26.74</td></tr><tr><td>Lumbosacral</td><td>18</td><td>20.93</td></tr><tr><td>Sacral</td><td>16</t... | <table><tr><td>Level of lesion</td><td>Number of patients</td><td>Percentage</td></tr></table> | <table><tr><td>Thoracic</td><td>3</td><td>3.49</td></tr><tr><td>Thoracolumbar</td><td>6</td><td>6.98</td></tr><tr><td>Lumbar</td><td>23</td><td>26.74</td></tr><tr><td>Lumbosacral</td><td>18</td><td>20.93</td></tr><tr><td>Sacral</td><td>16</td><td>18.60</td></tr><tr><td>Sacrococcygeal</td><td>1</td><td>1.16</td></tr><tr... |
29e3d19141535c8870d89fe5d5883b9fba65d69a3564ac1d58de736b3db11598.png | simple | <table><tr><td></td><td>β</td><td>t</td><td><i>p</i></td></tr><tr><td>Maternal age (per year)</td><td>−0.008</td><td>−0.45</td><td>0.65</td></tr><tr><td>Maternal weight (per kg)</td><td>0.211</td><td>11.77</td><td><0.001</td></tr><tr><td>Frozen thawed embryo (versus fresh embryo)</td><td>0.079</td><... | <table><tr><td></td><td>β</td><td>t</td><td>p</td></tr><tr><td>Maternal age (per year)</td><td>−0.008</td><td>−0.45</td><td>0.65</td></tr><tr><td>Maternal weight (per kg)</td><td>0.211</td><td>11.77</td><td><0.001</td></tr></table> | <table><tr><td>Frozen thawed embryo (versus fresh embryo)</td><td>0.079</td><td>4.25</td><td><0.001</td></tr><tr><td>ICSI (versus IVF)</td><td>0.009</td><td>0.48</td><td>0.63</td></tr><tr><td>SAGE (versus Vitrolife)</td><td>−0.004</td><td>−0.24</td><td>0.81</td></tr><tr><td>Gestational age</td><td>0.490</td><td>27.38</... |
175c447ec27452a109ec215e0f35c41bded47e6e5a834ad07a136e599349660d.png | complex | <table><tr><td></td><td colspan="2">Secretory uric acid transporter</td></tr><tr><td>Compound</td><td>OAT1</td><td>ABCG2</td></tr><tr><td>Lesinurad</td><td>3.90 ± 0.94</td><td>>100</td></tr></table> | <table><tr><td></td></tr><tr><td>Compound</td></tr><tr><td>Lesinurad</td></tr></table> | <table><tr><td colspan="2">Secretory uric acid transporter</td></tr><tr><td>OAT1</td><td>ABCG2</td></tr><tr><td>3.90 ± 0.94</td><td>>100</td></tr></table> |
01f004ad9f9d538f28dc1edd0dcc1844e8dae3b548d82f22bd77188fab23aede.png | simple | <table><tr><td>Pathway</td><td>Description</td></tr><tr><td>G protein-coupled receptor (GPCR) signaling</td><td>There are more than 800 GPR genes in the genome. These receptors activate adenyl cyclase to produce cAMP from ATP, or in the phosphatidylinositol pathway to produce a cell response, depending on the context. ... | <table><tr><td>Pathway</td><td>Description</td></tr><tr><td>G protein-coupled receptor (GPCR) signaling</td><td>There are more than 800 GPR genes in the genome. These receptors activate adenyl cyclase to produce cAMP from ATP, or in the phosphatidylinositol pathway to produce a cell response, depending on the context. ... | <table><tr><td>Pathway</td><td>Description</td></tr><tr><td>EGFR signaling</td><td>This receptor was markedly downregulated. In addition, SOS1 (present in cytosol) was upregulated in this pathway.</td></tr><tr><td>ErbB2 signaling</td><td>The ligand NRG1 and its receptors ErbB2 and ErbB3 were upregulated. The ErbB2 inte... |
076d9395afbeb921187a0c14965a1c07165ee3f25d19b3466bf129cc2f651928.png | complex | <table><tr><td>Characteristic</td><td>Case (<i>n</i> = 82)</td></tr><tr><td colspan="2">Age in years</td></tr><tr><td>> 45</td><td>21</td></tr><tr><td>≤ 45</td><td>61</td></tr><tr><td colspan="2">Sex</td></tr><tr><td> Male</td><td>33</td></tr><tr><td> Female</td><td>49</td></tr><tr><td>Tumour size, cm</td><td>... | <table><tr><td>Characteristic</td><td>Case (n = 82)</td></tr><tr><td colspan="2">Age in years</td></tr><tr><td>> 45</td><td>21</td></tr><tr><td>≤ 45</td><td>61</td></tr><tr><td colspan="2">Sex</td></tr><tr><td>Male</td><td>33</td></tr><tr><td>Female</td><td>49</td></tr><tr><td>Tumour size, cm</td><td>5.94 ± 2.65</td></... | <table><tr><td>Characteristic</td><td>Case (n = 82)</td></tr><tr><td colspan="2">Tumour thrombus</td></tr><tr><td>Negative</td><td>72</td></tr><tr><td>Positive</td><td>10</td></tr></table> |
338d39e857491843816fd7d7f24cdff0d7763acf4e6edd505b8fe1d939c03caa.png | complex | <table><tr><td>Annual Report Year</td><td>Case Number</td><td>Clinical Summary</td></tr><tr><td colspan="3">Patients Treated with FabAV</td></tr><tr><td>2001</td><td>55</td><td>A 17-year-old girl presented after apparent intravascular envenomation by an unknown snake with features of anaphylaxis to venom. Within minute... | <table><tr><td>Annual Report Year</td><td>Case Number</td><td>Clinical Summary</td></tr><tr><td colspan="3">Patients Treated with FabAV</td></tr><tr><td>2001</td><td>55</td><td>A 17-year-old girl presented after apparent intravascular envenomation by an unknown snake with features of anaphylaxis to venom. Within minute... | <table><tr><td>2004</td><td>52</td><td>A 52-year-old man presented with a forearm compartment syndrome due to a copperhead snakebite. He received FabAV and underwent a dermotomy of his finger and a fasciotomy of his arm. Subsequently, he developed severe alcohol withdrawal, which was treated with diazepam, haloperidol,... |
14a3a99918799915737ddf9a6f917de9730463928db42646c88c84893e764c73.png | complex | <table><tr><td rowspan="2">Groups</td><td rowspan="2">Dose (mg/Kg bw)</td><td colspan="3">Blood antioxidant enzymes</td></tr><tr><td>SOD (U/g Hb)</td><td>GPX (U/g Hb)</td><td>CAT (K/g Hb)</td></tr><tr><td>NC</td><td>-</td><td>2943 ± 104.4 <sup>a</sup></td><td>51.31±4.2<sup>a</sup></td><td>1.57 ± 0.6<sup>... | <table><tr><td rowspan="2">Groups</td><td rowspan="2">Dose (mg/Kg bw)</td><td colspan="3">Blood antioxidant enzymes</td></tr><tr><td>SOD (U/g Hb)</td><td>GPX (U/g Hb)</td><td>CAT (K/g Hb)</td></tr><tr><td>NC</td><td>-</td><td>2943 ± 104.4 a</td><td>51.31±4.2a</td><td>1.57 ± 0.6a</td></tr></table> | <table><tr><td>DC</td><td>-</td><td>1945.8 ± 21.6</td><td>33.11 ± 3.74</td><td>0.541 ± 0.011</td></tr><tr><td>ASE+D</td><td>500</td><td>3125.4 ± 54.2 a</td><td>42.2 ± 5.21b</td><td>0.882 ± 0.12 c</td></tr><tr><td>AAE+D</td><td>500</td><td>3214.3 ± 83.2 a</td><td>47.5 ± 4.2 a</td><td>0.839 ± 0.09 c</td></tr><tr><td>SOE+... |
7f5ca12fa38da089aaaab93823e53eed1b6debb727b0f7186139f2381ccf1e8a.png | simple | <table><tr><td></td><td>NanoString FROZ vs FFPE</td><td>ScriptSeq FROZ vs FFPE</td></tr><tr><td>BRB123</td><td>0.926 (0.950)</td><td>0.790 (0.943)</td></tr><tr><td>BRB144</td><td>0.955 (0.965)</td><td>0.807 (0.957)</td></tr><tr><td>BRB147</td><td>0.728 (0.917)</td><td>0.802 (0.945)</td></tr><tr><td>BRB157</td><td>0.807... | <table><tr><td></td><td>NanoString FROZ vs FFPE</td><td>ScriptSeq FROZ vs FFPE</td></tr><tr><td>BRB123</td><td>0.926 (0.950)</td><td>0.790 (0.943)</td></tr><tr><td>BRB144</td><td>0.955 (0.965)</td><td>0.807 (0.957)</td></tr><tr><td>BRB147</td><td>0.728 (0.917)</td><td>0.802 (0.945)</td></tr><tr><td>BRB157</td><td>0.807... | <table><tr><td>BRB212</td><td>0.972 (0.962)</td><td>0.830 (0.963)</td></tr><tr><td>BRB215</td><td>0.818 (0.976)</td><td>0.598 (0.961)</td></tr><tr><td>BRB248</td><td>0.942 (0.976)</td><td>0.830 (0.972)</td></tr><tr><td>BRB277</td><td>0.973 (0.970)</td><td>0.825 (0.971)</td></tr><tr><td>MCJBCR028</td><td>0.747 (0.941)</... |
7418a5ef129f99c2c13ec6b242cb021bac9417cc512af7d76118ccd232011728.png | simple | <table><tr><td></td><td><i>N</i></td><td>Drug</td><td>Duration</td><td>Subcutaneous adipose tissue</td><td>Visceral adipose tissue</td><td>Body mass index (kg/m<sup>2</sup>)</td><td>Reference</td></tr><tr><td>No change in SAT</td><td>30</td><td>Rosi versus placebo</td><td>24 weeks</td><td>MRI: NS</td><td>MRI: NS</td><t... | <table><tr><td></td><td>N</td><td>Drug</td><td>Duration</td><td>Subcutaneous adipose tissue</td><td>Visceral adipose tissue</td><td>Body mass index (kg/m2)</td><td>Reference</td></tr><tr><td>No change in SAT</td><td>30</td><td>Rosi versus placebo</td><td>24 weeks</td><td>MRI: NS</td><td>MRI: NS</td><td>NS</td><td>Sutin... | <table><tr><td></td><td>N</td><td>Drug</td><td>Duration</td><td>Subcutaneous adipose tissue</td><td>Visceral adipose tissue</td><td>Body mass index (kg/m2)</td><td>Reference</td></tr><tr><td></td><td>108</td><td>Rosi versus placebo</td><td>48 weeks</td><td>DEXA limb fat: NS CT thigh: NS CT s.c. abdomen: NS</td><td>CT: ... |
68acf21e48a4a9bd740a99e2894dc1cd4e4e5753735d9bd770b91563ff1be016.png | simple | <table><tr><td></td><td>Group A (non-GBA)</td><td>Group B (GBA)</td><td><i>P</i> value</td></tr><tr><td>Neck lymphadenopathy</td><td>26/60 (43%)</td><td>7/14 (50%)</td><td>NS</td></tr><tr><td>Fissured lips</td><td>53/60 (88%)</td><td>12/14 (86%)</td><td>NS</td></tr><tr><td>Strawberry tongue</td><td>47/61 (77%)</td><td>... | <table><tr><td></td><td>Group A (non-GBA)</td><td>Group B (GBA)</td><td>P value</td></tr><tr><td>Neck lymphadenopathy</td><td>26/60 (43%)</td><td>7/14 (50%)</td><td>NS</td></tr><tr><td>Fissured lips</td><td>53/60 (88%)</td><td>12/14 (86%)</td><td>NS</td></tr><tr><td>Strawberry tongue</td><td>47/61 (77%)</td><td>11/14 (... | <table><tr><td>BCG erythema change</td><td>25/58 (43%)</td><td>6/13 (46%)</td><td>NS</td></tr><tr><td>Induration of extremities</td><td>39/56 (70%)</td><td>3/12 (25%)</td><td>NS</td></tr></table> |
6a796850c3dc37e6814a39cd01cf390a059c3db7f356896f9fc0917a603de84b.png | simple | <table><tr><td>Heuristic</td><td>Network load (No. of groups)</td><td>Channel Constraint (<i>ω</i>)</td><td>Radio Constraint</td><td>Network Size</td><td>Communication Radius</td></tr><tr><td>SPT</td><td>(200%, 200%)*</td><td>(175%, 150%)</td><td>(400%, 350%)</td><td>(300%, 142%)</td><td>(180%, 175%)</td></tr><tr>... | <table><tr><td>Heuristic</td><td>Network load (No. of groups)</td><td>Channel Constraint (ω)</td><td>Radio Constraint</td><td>Network Size</td><td>Communication Radius</td></tr><tr><td>SPT</td><td>(200%, 200%)*</td><td>(175%, 150%)</td><td>(400%, 350%)</td><td>(300%, 142%)</td><td>(180%, 175%)</td></tr><tr><td>GIT</td>... | <table><tr><td>Heuristic</td><td>Channel Constraint (ω)</td><td>Radio Constraint</td><td>Network Size</td><td>Communication Radius</td></tr><tr><td>CR</td><td>17%, 25%)</td><td> 100%)</td><td>)</td><td>, 92%)</td></tr></table> |
0c1dae09fa84325b6cc5035911318cd56cb654eede2b5e664787a77f9fbd295c.png | simple | <table><tr><td>AMPLICON</td><td>SSCP ANALYSIS</td><td>HRMA/SEQUENCING<sup>1</sup></td><td>N. OF CASES</td></tr><tr><td>EXON 1</td><td>WT</td><td>WT</td><td>26</td></tr><tr><td>EXON 2</td><td>WT</td><td>WT</td><td>23</td></tr><tr><td></td><td>WT</td><td>c.[64G > A]+[=]</td><td>1</td></tr><tr><td></td><td>c.[64G > ... | <table><tr><td>AMPLICON</td><td>SSCP ANALYSIS</td></tr><tr><td>EXON 1</td><td>WT</td></tr><tr><td>EXON 2</td><td>WT</td></tr><tr><td></td><td>WT</td></tr><tr><td></td><td>c.[64G > A]+[64G > A]</td></tr><tr><td>EXON 3</td><td>WT</td></tr><tr><td>EXON 4</td><td>WT</td></tr><tr><td>EXON 5</td><td>WT</td></tr><tr><td>EXON ... | <table><tr><td>HRMA/SEQUENCING1</td><td>N. OF CASES</td></tr><tr><td>WT</td><td>26</td></tr><tr><td>WT</td><td>23</td></tr><tr><td>c.[64G > A]+[=]</td><td>1</td></tr><tr><td>c.[64G > A]+[64G > A]</td><td>2</td></tr><tr><td>WT</td><td>26</td></tr><tr><td>WT</td><td>26</td></tr><tr><td>WT</td><td>26</td></tr><tr><td>WT</... |
7a07100dc01ffa72363bee3236284c23e2fa089621777cc8eecc2fd65dba7bd1.png | complex | <table><tr><td rowspan="2">Essential oil</td><td colspan="2"><i>S. pyogenes</i></td><td colspan="2"><i>S. pneumoniae</i></td><td colspan="2"><i>S. mutans</i></td></tr><tr><td>MIC</td><td>MBC</td><td>MIC</td><td>MBC</td><td>MIC</td><td>MBC</td></tr><tr><td>Cinnamon bark</td><td>0.41</td><td>0.81</td><td>0.06</td><td>0.1... | <table><tr><td rowspan="2">Essential oil</td><td>S. pyogenes</td></tr><tr><td>MIC</td></tr><tr><td>Cinnamon bark</td><td>0.41</td></tr><tr><td>Thyme</td><td>0.43</td></tr><tr><td>Clove</td><td>0.10</td></tr><tr><td>Peppermint</td><td>0.35</td></tr><tr><td>Citronella</td><td>0.17</td></tr><tr><td>Eucalyptus</td><td>2.82... | <table><tr><td>S. pyogenes</td><td colspan="2">S. pneumoniae</td><td colspan="2">S. mutans</td></tr><tr><td>MBC</td><td>MIC</td><td>MBC</td><td>MIC</td><td>MBC</td></tr><tr><td>0.81</td><td>0.06</td><td>0.13</td><td>0.20</td><td>0.41</td></tr><tr><td>0.87</td><td>0.11</td><td>0.22</td><td>0.04</td><td>0.09</td></tr><tr... |
d575b9521bced00a961c16b37711c323310fa047d6d094c1818bad359f25e0da.png | complex | <table><tr><td>Stimulus 1</td><td>Stimulus 2</td><td>95% CI Lower bound</td><td>Difference of Means (1–2)</td><td>95% CI Upper bound</td><td><i>P</i></td></tr><tr><td colspan="6">TOTALLY ENGAGED (<i>N</i> = 27)</td></tr><tr><td>Audio only</td><td>Multimodal</td><td>–39.72</td><td>–28.33</td><td>–... | <table><tr><td>Stimulus 1</td><td>Stimulus 2</td><td>95% CI Lower bound</td><td>Difference of Means (1–2)</td><td>95% CI Upper bound</td><td>P</td></tr><tr><td colspan="6">TOTALLY ENGAGED (N = 27)</td></tr><tr><td>Audio only</td><td>Multimodal</td><td>–39.72</td><td>–28.33</td><td>–16.95</td><td><0.001</td></tr><tr><td... | <table><tr><td>Stimulus 1</td><td>Stimulus 2</td><td>95% CI Lower bound</td><td>Difference of Means (1–2)</td><td>95% CI Upper bound</td><td>P</td></tr><tr><td>Audio only</td><td>Multimodal</td><td>–3.81</td><td>6.19</td><td>16.18</td><td>0.3023</td></tr><tr><td>Music: FAV</td><td>Audio only</td><td>–27.47</td><td>–17.... |
b0b035e9477fe547dabe265625779fea7f815c3f699367cd88de4c1769d6fa7c.png | complex | <table><tr><td>Activities Related to HAI Prevention</td><td>Professional Groups</td><td><i>N</i></td><td>Average Values in Groups</td><td>Median</td><td>Standard Deviation</td><td>95% CI</td></tr><tr><td rowspan="3">Hand-hygiene</td><td>Medical student</td><td>28</td><td>5.6</td><td>6.0</td><td>2.71</td><td>4.649, 6.49... | <table><tr><td>Activities Related to HAI Prevention</td><td>Professional Groups</td><td>N</td><td>Average Values in Groups</td><td>Median</td><td>Standard Deviation</td></tr><tr><td rowspan="3">Hand-hygiene</td><td>Medical student</td><td>28</td><td>5.6</td><td>6.0</td><td>2.71</td></tr><tr><td>Medical intern</td><td>1... | <table><tr><td>95% CI</td></tr><tr><td>4.649, 6.494</td></tr><tr><td>4.873, 7.571</td></tr><tr><td>5.241, 6.759</td></tr><tr><td>6.016, 7.198</td></tr><tr><td>3.724, 6.276</td></tr><tr><td>4.229, 5.548</td></tr><tr><td>4.451, 5.978</td></tr><tr><td>4.255, 6.745</td></tr><tr><td>4.616, 6.051</td></tr></table> |
95f6d32a67381cacef7883fdcd3f5a3fb0a8b351a80504a1d3699a99125cc178.png | complex | <table><tr><td></td><td colspan="4">urine pH > 5.5 (idRTA)</td><td colspan="4">urine pH < 5.5</td><td>p</td></tr><tr><td></td><td>Baseline</td><td>3 months</td><td>6 months</td><td>9 months</td><td>Baseline</td><td>3 months</td><td>6 months</td><td>9 months</td><td></td></tr><tr><td>serum alkaline phosphate (U/L)... | <table><tr><td></td><td colspan="4">urine pH > 5.5 (idRTA)</td><td colspan="4">urine pH < 5.5</td><td>p</td></tr><tr><td></td><td>Baseline</td><td>3 months</td><td>6 months</td><td>9 months</td><td>Baseline</td><td>3 months</td><td>6 months</td><td>9 months</td><td></td></tr><tr><td>serum alkaline phosphate (U/L)mean (... | <table><tr><td>Mean height velocity range (cm)</td><td>4.50 -8.00</td><td></td><td></td><td></td><td>4.00 - 8.40</td><td></td><td></td><td></td><td></td></tr></table> |
2d976160d34a7172258c2f1601cba7e853d9348280261b9cdd380b7c34106038.png | simple | <table><tr><td>Identified Motif Sequence</td><td># Seqs withMotif</td><td>Motif E-Value</td><td>TRANS FAC Hit ID</td><td>TRANS AC Binding Site Sequence</td><td>TRANS FAC annotation</td></tr><tr><td>CATCCAACGGC</td><td>29</td><td>1.2E-1</td><td>M00227</td><td>TCCAACGGC</td><td>Myb</td></tr><tr><td>CCCGCCACGCGCCAC</td><t... | <table><tr><td>Identified Motif Sequence</td><td># Seqs withMotif</td><td>Motif E-Value</td><td>TRANS FAC Hit ID</td><td>TRANS AC Binding Site Sequence</td><td>TRANS FAC annotation</td></tr><tr><td>CATCCAACGGC</td><td>29</td><td>1.2E-1</td><td>M00227</td><td>TCCAACGGC</td><td>Myb</td></tr><tr><td>CCCGCCACGCGCCAC</td><t... | <table><tr><td>AGCGAGCGAGC</td><td>4</td><td>6.23E-8</td><td>No Hit</td></tr><tr><td>AGCAAGCTAGC</td><td>3</td><td>2.47E-7</td><td>No Hit</td></tr></table> |
9d6c6b6f03e438ce6060377c2b76125a75a6d839d88a58f98ceb4feb71d1d276.png | simple | <table><tr><td></td><td>Number</td><td>Percentage (%)</td></tr><tr><td>1 year follow up</td><td>66</td><td>81.5</td></tr><tr><td>Lost to follow up</td><td>5</td><td>6</td></tr><tr><td>Deceased at 1 year</td><td>10</td><td>12.3</td></tr><tr><td>Referral done to specialized cardiology center</td><td>37</td><td>45.6</td><... | <table><tr><td></td><td>Number</td><td>Percentage (%)</td></tr><tr><td>1 year follow up</td><td>66</td><td>81.5</td></tr><tr><td>Lost to follow up</td><td>5</td><td>6</td></tr></table> | <table><tr><td></td><td>Number</td><td>Percentage (%)</td></tr><tr><td>Deceased at 1 year</td><td>10</td><td>12.3</td></tr><tr><td>Referral done to specialized cardiology center</td><td>37</td><td>45.6</td></tr><tr><td>Underwent Exercise ECG</td><td>22</td><td>27</td></tr><tr><td>Underwent Coronary angiogram</td><td>10... |
e2f1208ba786b914631177c52ff85fcd9c204f7489633c6035e7ab3eb00f17ae.png | simple | <table><tr><td>Modification</td><td>Hypotheses tested</td></tr><tr><td>Ranking task</td><td>Introducing the ranking task prior to the cTTO valuation will reduce the inconsistencies and improves the overall data quality (i.e. more WTD responses).</td></tr><tr><td>BTD/WTD split</td><td>Separating the BTD and WTD cTTO tas... | <table><tr><td>Modification</td><td>Hypotheses tested</td></tr><tr><td>Ranking task</td><td>Introducing the ranking task prior to the cTTO valuation will reduce the inconsistencies and improves the overall data quality (i.e. more WTD responses).</td></tr><tr><td>BTD/WTD split</td><td>Separating the BTD and WTD cTTO tas... | <table><tr><td>Feedback module</td><td>Presenting respondents with the rank ordering implied by their cTTO valuations will reduce the inconsistencies as they will identify and flag problematic valuations for removal from the data.</td></tr></table> |
69f72db68beb2c0a4287ed2b603749d8840a2eedb76b699b5e057fc0a57275d2.png | simple | <table><tr><td>Viroid small RNAs (vd-sRNAs)</td><td>Reference</td></tr><tr><td>vd-sRNAs of peach latent mosaic viroid were used to study the viroid evolution and pathogenesis</td><td>Di Serio et al., 2009; Navarro et al., 2012a</td></tr><tr><td>Gaining further insights into the genesis and role of vd-RNAs of hop stunt ... | <table><tr><td>Viroid small RNAs (vd-sRNAs)</td><td>Reference</td></tr><tr><td>vd-sRNAs of peach latent mosaic viroid were used to study the viroid evolution and pathogenesis</td><td>Di Serio et al., 2009; Navarro et al., 2012a</td></tr><tr><td>Gaining further insights into the genesis and role of vd-RNAs of hop stunt ... | <table><tr><td>Viroid small RNAs (vd-sRNAs)</td><td>Reference</td></tr><tr><td>e utilized to identify circular RNAs of viroid or satellite sRNAs</td><td>et al., 2014</td></tr><tr><td>Extending the host range of apple dimple fruit viroid to fig</td><td>Chiumenti et al., 2014</td></tr><tr><td>Inoculation with a single va... |
4526840ac44e1c429c75e03afeb2946241b4800bcf5c21c018fdbe4f5af0d75c.png | complex | <table><tr><td rowspan="2">Species</td><td rowspan="2">Specimen voucher</td><td colspan="4"><i>cox</i>1<sup><i>a</i></sup></td><td colspan="4">ITS-2<sup>b</sup></td></tr><tr><td>GenBank accession no.</td><td>Length (bp)</td><td>G+C content (%)</td><td>Pairwise difference (%)</td><td>GenBank accession no.</td><td>Length... | <table><tr><td rowspan="2">Species</td><td rowspan="2">Specimen voucher</td><td colspan="4">cox1a</td><td colspan="4">ITS-2b</td></tr><tr><td>GenBank accession no.</td><td>Length (bp)</td><td>G+C content (%)</td><td>Pairwise difference (%)</td><td>GenBank accession no.</td><td>Length (bp)</td><td>G+C content (%)</td><t... | <table><tr><td rowspan="2">Species</td><td rowspan="2">Specimen voucher</td><td colspan="4">cox1a</td><td colspan="4">ITS-2b</td></tr><tr><td>GenBank accession no.</td><td>Length (bp)</td><td>G+C content (%)</td><td>Pairwise difference (%)</td><td>GenBank accession no.</td><td>Length (bp)</td><td>G+C content (%)</td><t... |
c32fcb0e0118c88a3a96412e8581206ba1ef06cb0ff6984f1ea5e7c4c05c7217.png | complex | <table><tr><td>Parameter</td><td colspan="2">Value</td></tr><tr><td></td><td colspan="2">n = 4068</td></tr><tr><td>Age (n,%)</td><td></td><td></td></tr><tr><td> 18-34</td><td>20</td><td>0.5</td></tr><tr><td> 35-44</td><td>108</td><td>2.7</td></tr><tr><td> 45-54</td><td>513</td><td>12.6</td></tr><tr><td> 55-64</td><td>1... | <table><tr><td>Parameter</td></tr><tr><td></td></tr><tr><td>Age (n,%)</td></tr><tr><td>18-34</td></tr><tr><td>35-44</td></tr><tr><td>45-54</td></tr><tr><td>55-64</td></tr><tr><td>> = 65</td></tr><tr><td>Geographic region (n,%)</td></tr><tr><td>Northeast</td></tr><tr><td>Northcentral</td></tr><tr><td>South</td></tr><tr>... | <table><tr><td colspan="2">Value</td></tr><tr><td colspan="2">n = 4068</td></tr><tr><td></td><td></td></tr><tr><td>20</td><td>0.5</td></tr><tr><td>108</td><td>2.7</td></tr><tr><td>513</td><td>12.6</td></tr><tr><td>1,481</td><td>36.4</td></tr><tr><td>1,946</td><td>47.8</td></tr><tr><td></td><td></td></tr><tr><td>538</td... |
344c047d125c8b8fce7adbac1aa7cffe188723c542bbe3dd679b10d8c25321b4.png | complex | <table><tr><td>Combination</td><td colspan="3">Nr of MRSA strains (%) for which combinations gave</td></tr><tr><td></td><td>Synergy</td><td>No interaction</td><td>Antagonism</td></tr><tr><td>LVX + VA (n = 50)</td><td>16 (32)</td><td>34 (68)</td><td>0</td></tr><tr><td>LVX + TEC (n = 50)</td><td>9 (18)</td><td>41 (82)</t... | <table><tr><td>Combination</td><td colspan="3">Nr of MRSA strains (%) for which combinations gave</td></tr></table> | <table><tr><td></td><td>Synergy</td><td>No interaction</td><td>Antagonism</td></tr><tr><td>LVX + VA (n = 50)</td><td>16 (32)</td><td>34 (68)</td><td>0</td></tr><tr><td>LVX + TEC (n = 50)</td><td>9 (18)</td><td>41 (82)</td><td>0</td></tr><tr><td>CTX + VA (n = 50)</td><td>23 (46)</td><td>27 (54)</td><td>0</td></tr><tr><t... |
81dc4443e2381ce07b834592708047f19ea47c10afca1ab8ef86a0b99dee720b.png | complex | <table><tr><td></td><td>Attack-free periods Mean ± S.D.</td><td>Control Mean ± S.D.</td><td>P</td></tr><tr><td>IOP, mmHg</td><td><i>14,11 ± 2,88</i></td><td>15,81 ± 0,81</td><td rowspan="2">0,07</td></tr><tr><td>Range</td><td>(11–20)</td><td>(11–20)</td></tr><tr><td>AL, mm</td><td>23,08 ... | <table><tr><td></td><td>Attack-free periods Mean ± S.D.</td><td>Control Mean ± S.D.</td><td>P</td></tr><tr><td>IOP, mmHg</td><td>14,11 ± 2,88</td><td>15,81 ± 0,81</td><td rowspan="2">0,07</td></tr><tr><td>Range</td><td>(11–20)</td><td>(11–20)</td></tr><tr><td>AL, mm</td><td>23,08 ± 1,2</td><td>23,3 ± 0,7</td><td>0,4</t... | <table><tr><td>K2, D</td><td>44,23 ± 2,03</td><td>44,19 ± 1,50</td><td>0,9</td></tr><tr><td>LT, mm</td><td>4,47 ± 3,75</td><td>3,76 ± 0,31</td><td>0,3</td></tr><tr><td>PD, mm</td><td>5,99 ± 0,92</td><td>5,81 ± 1,07</td><td>0,4</td></tr><tr><td>WtW, mm</td><td>12,20 ± 0,44</td><td></td><td>0,112</td></tr></table> |
7a3c4d265f40377bac54487b45b714ba7d43d5f8a701f4c4f58c80c61c34c59a.png | simple | <table><tr><td>Gene</td><td>Number of exons</td><td>Number of mutations worldwide**</td><td>Number of homopolymer repeats* in CDS</td><td>Function in hearing process</td></tr><tr><td><i>GJB2</i></td><td>2</td><td>> 220</td><td>0</td><td>ion homeostasis</td></tr><tr><td><i>SLC26A4</i></td><td>21</td><td>43</td><td>7<... | <table><tr><td>Gene</td><td>Number of exons</td><td>Number of mutations worldwide**</td></tr><tr><td>GJB2</td><td>2</td><td>> 220</td></tr><tr><td>SLC26A4</td><td>21</td><td>43</td></tr><tr><td>MYO15A</td><td>66</td><td>28</td></tr><tr><td>OTOF</td><td>48</td><td>26</td></tr><tr><td>CDH23</td><td>69</td><td>21</td></tr... | <table><tr><td>Number of homopolymer repeats* in CDS</td><td>Function in hearing process</td></tr><tr><td>0</td><td>ion homeostasis</td></tr><tr><td>7</td><td>ion homeostasis</td></tr><tr><td>8</td><td>hair bundle, motor protein</td></tr><tr><td>4</td><td>exocytose at auditory ribbon synapse</td></tr><tr><td>4</td><td>... |
50da0d33ff7a4b971732535ddf6f227fbf25b07f97e2144f417c740529eda003.png | complex | <table><tr><td rowspan="3">Parameter</td><td colspan="6">Mean value for group ± SE<sup><i>a</i></sup></td></tr><tr><td rowspan="2">NI</td><td rowspan="2">Pretherapy (120 dpi)</td><td colspan="4">Posttherapy (180–200 dpi)</td></tr><tr><td>Veh</td><td>PTX</td><td>Bz</td><td>Bz+PTX</td></tr><tr><td>Parasitemia ... | <table><tr><td>Parameter</td><td colspan="6">Mean value for group ± SEa</td></tr></table> | <table><tr><td rowspan="2">Parameter</td><td rowspan="2">NI</td><td rowspan="2">Pretherapy (120 dpi)</td><td colspan="4">Posttherapy (180–200 dpi)</td></tr><tr><td>Veh</td><td>PTX</td><td>Bz</td><td>Bz+PTX</td></tr><tr><td>Parasitemia level (104 parasites/ml)</td><td>0</td><td>53 ± 10</td><td>56 ± 45</td><td>23 ± 8.5 #... |
609a9bf23144ac74c901d3e0ba1507b6dba7274205e0dd13ba3ea3f27ca6010d.png | complex | <table><tr><td rowspan="2">Parameter</td><td colspan="3">Temperature (K)</td></tr><tr><td>293 </td><td>303 </td><td>313 </td></tr><tr><td>−Δ<i>G</i>° (kJ mol<sup>−1</sup>)</td><td>6.543</td><td>6.063</td><td>5.687</td></tr><tr><td>−Δ<i>H</i>° (kJ mol<sup>−1</sup>)</td><td>16.... | <table><tr><td rowspan="2">Parameter</td><td colspan="3">Temperature (K)</td></tr><tr><td>293</td><td>303</td><td>313</td></tr><tr><td>−ΔG° (kJ mol−1)</td><td>6.543</td><td>6.063</td><td>5.687</td></tr><tr><td>−ΔH° (kJ mol−1)</td><td>16.869</td><td></td><td></td></tr></table> | <table><tr><td>−ΔS° (kJ mol−1 K−1)</td><td>0.0353</td></tr><tr><td>Ea (kJ mol−1)</td><td>3.309</td></tr></table> |
a327b8cca8006d6f7c06986145863ba2e641b9cbfdee803a533298b60a004b3f.png | simple | <table><tr><td>Temperature (°C)</td><td>−40</td><td>−20</td><td>0</td><td>+20</td><td>+40</td><td>+60</td></tr><tr><td>Resonant frequency of the upper resonator (Hz)</td><td>31,331.12</td><td>31,379.3</td><td>31,426.16</td><td>31,462.37</td><td>31,496.56</td><td>31,514.02</td></tr><tr><td>Resonant freq... | <table><tr><td>Temperature (°C)</td><td>−40</td><td>−20</td><td>0</td><td>+20</td><td>+40</td><td>+60</td></tr></table> | <table><tr><td>Resonant frequency of the upper resonator (Hz)</td><td>31,331.12</td><td>31,379.3</td><td>31,426.16</td><td>31,462.37</td><td>31,496.56</td><td>31,514.02</td></tr><tr><td>Resonant frequency of the lower resonator (Hz)</td><td>31,439.55</td><td>31,486.05</td><td>31,531.33</td><td>31,565.55</td><td>31,598.... |
a6ecd755c552375672789dd1962a36c614adf6104321133a04609f3085c38769.png | simple | <table><tr><td>Participant code</td><td>Sex</td><td>Age (yrs)</td><td>BMI (kg/m<sup>2</sup>)</td><td>Injury level and AIS score</td><td>Years since SCI</td><td>Medications</td><td>Treatment</td></tr><tr><td>1</td><td>M</td><td>46</td><td>32.9</td><td>C5A</td><td>23.3</td><td>Baclofen, Temazepam</td><td>CPAP</td></tr><t... | <table><tr><td>Participant code</td><td>Sex</td><td>Age (yrs)</td><td>BMI (kg/m2)</td><td>Injury level and AIS score</td><td>Years since SCI</td><td>Medications</td><td>Treatment</td></tr><tr><td>1</td><td>M</td><td>46</td><td>32.9</td><td>C5A</td><td>23.3</td><td>Baclofen, Temazepam</td><td>CPAP</td></tr></table> | <table><tr><td>2</td><td>M</td><td>68</td><td>27.7</td><td>C4A</td><td>23.9</td><td>Baclofen</td><td>CPAP</td></tr><tr><td>3</td><td>F</td><td>28</td><td>20.3</td><td>C5A</td><td>4.10</td><td>Baclofen, Diazepam</td><td>—</td></tr><tr><td>4</td><td>M</td><td>42</td><td>20.8</td><td>C6A</td><td>17.10</td><td>Baclofen, Di... |
65bda91d12487ccb97d2350910e10214894bd133ee6f2e32ba9df100f737e7b8.png | complex | <table><tr><td> </td><td> </td><td colspan="2">Women</td><td colspan="2">Men</td></tr><tr><td> </td><td> </td><td colspan="2">N = 214</td><td colspan="2">N = 154</td></tr><tr><td> </td><td> </td><td>OR</td><td>p</td><td>OR</td><td>p</td></tr><tr><td>Surgical specialties</td><td>Combining work with family</td><td>0.4 (0... | <table><tr><td></td><td></td><td colspan="2">Women</td><td colspan="2">Men</td></tr><tr><td></td><td></td><td colspan="2">N = 214</td><td colspan="2">N = 154</td></tr><tr><td></td><td></td><td>OR</td><td>p</td><td>OR</td><td>p</td></tr><tr><td>Surgical specialties</td><td>Combining work with family</td><td>0.4 (0.3–0.6... | <table><tr><td></td><td>Lots of direct patient contact</td><td>0.6 (0.4–0.8)</td><td>.003</td><td>1.0 (0.7–1.5)</td><td>NS</td></tr></table> |
d9f4a228207e26fbd3dd1feac24d3fc15c4f90f4bd3d84754cf1832653aeeeb8.png | simple | <table><tr><td>Characteristics</td><td>THC score mean (SE)</td><td>CH score mean (SE)</td><td>PH score mean (SE)</td><td><i>P</i> value</td></tr><tr><td>First contact and continuity</td><td>95.40 (0.39)</td><td>90.93 (0.52)</td><td>85.23 (0.51)</td><td><0.001</td></tr><tr><td>Comprehensiveness (medical care)</td><td... | <table><tr><td>Characteristics</td><td>THC score mean (SE)</td><td>CH score mean (SE)</td><td>PH score mean (SE)</td><td>P value</td></tr><tr><td>First contact and continuity</td><td>95.40 (0.39)</td><td>90.93 (0.52)</td><td>85.23 (0.51)</td><td><0.001</td></tr><tr><td>Comprehensiveness (medical care)</td><td>80.9 (0.9... | <table><tr><td>Characteristics</td><td>THC score mean (SE)</td><td>CH score mean (SE)</td><td>PH score mean (SE)</td><td>P value</td></tr><tr><td>Family centeredness</td><td>90.34 (0.68)</td><td>87.93 (0.60)</td><td>84.18 (0.53)</td><td><0.001</td></tr><tr><td>Community orientation</td><td>87.98 (0.87)</td><td>80.36 (0... |
64614a2c87183ea4fced537834c7c9e1550ddef18f72a3b13ef598a943c3d59b.png | complex | <table><tr><td>Authors</td><td>Intervention</td><td>Patient Population</td><td>Design</td><td>No. of Patients</td><td>Outcome</td></tr><tr><td rowspan="2">Pizzocarro et al<sup>15</sup></td><td rowspan="2">IFN-α2b <i>v</i> placebo</td><td rowspan="2">Robson stages II and III (T3aN0M0 and T3bN0M0 or T2/3N1-3M0)</td>... | <table><tr><td>Authors</td><td>Intervention</td><td>Patient Population</td><td>Design</td><td>No. of Patients</td><td>Outcome</td></tr><tr><td rowspan="2">Pizzocarro et al15</td><td rowspan="2">IFN-α2b v placebo</td><td rowspan="2">Robson stages II and III (T3aN0M0 and T3bN0M0 or T2/3N1-3M0)</td><td rowspan="2">Multice... | <table><tr><td rowspan="2">18</td><td rowspan="2"> IFN-α v observation</td><td rowspan="2">, T3 a-b-c; pN0-pN3, M0</td><td rowspan="2">randomized, controlled trial</td><td rowspan="2">0</td><td>l) v 0.73 (treatment)</td></tr><tr><td>10-year DFS: 0.60 (control) v 0.73 (treatment) (HR 0.84; 95% CI, 0.54–1.33, P = 0.47)</... |
9cbc7db15d5507d810ead300e7144942aa102881844e8f20a080dc57f636df25.png | simple | <table><tr><td>Species</td><td>Fu’s <i>FS</i></td><td>Tajima’s <i>D</i></td><td>SSD</td><td><i>rg</i></td></tr><tr><td><i>H. bovis</i></td><td>−12.795***</td><td>−2.031 **</td><td>0.001</td><td>0.035</td></tr><tr><td><i>H. sinense</i></td><td>−19.809***</td><td>−2.320**</td><td>0.001... | <table><tr><td>Species</td><td>Fu’s FS</td><td>Tajima’s D</td><td>SSD</td><td>rg</td></tr></table> | <table><tr><td>H. bovis</td><td>−12.795***</td><td>−2.031 **</td><td>0.001</td><td>0.035</td></tr><tr><td>H. sinense</td><td>−19.809***</td><td>−2.320**</td><td>0.001</td><td>0.033</td></tr></table> |
e759968a4778e9d325a31ea72e252f0fff40ad908fe50b8e268222cb0bf1f2bf.png | simple | <table><tr><td>Primary</td><td>Definition</td></tr><tr><td>Tumor (T)</td><td></td></tr><tr><td>Tx</td><td>Primary tumor cannot be assessed</td></tr><tr><td>T0</td><td>No evidence of primary tumor</td></tr><tr><td>Tis</td><td>Carcinoma in situ</td></tr><tr><td>T1</td><td>Tumor 2 cm or less in greatest dimension and no m... | <table><tr><td>Primary</td></tr><tr><td>Tumor (T)</td></tr><tr><td>Tx</td></tr><tr><td>T0</td></tr><tr><td>Tis</td></tr><tr><td>T1</td></tr><tr><td>T2</td></tr><tr><td>T3</td></tr><tr><td>T4a</td></tr><tr><td>T4b</td></tr></table> | <table><tr><td>Definition</td></tr><tr><td></td></tr><tr><td>Primary tumor cannot be assessed</td></tr><tr><td>No evidence of primary tumor</td></tr><tr><td>Carcinoma in situ</td></tr><tr><td>Tumor 2 cm or less in greatest dimension and no medullary bone invasion</td></tr><tr><td>Tumor more than 2 cm but not more than ... |
bbdfd8defba185c77201196f24d50efe0e442122d3fe069b818ede18902d2920.png | simple | <table><tr><td>Location of study village</td><td>Types of prevention practices reported</td><td>Frequency & motivation for bed net use</td><td>Influences on preventative health behaviours</td><td>Community suggestions for participation in malaria elimination</td></tr><tr><td>North Tanna</td><td>Use of bed netsClean... | <table><tr><td>Location of study village</td><td>Types of prevention practices reported</td><td>Frequency & motivation for bed net use</td><td>Influences on preventative health behaviours</td><td>Community suggestions for participation in malaria elimination</td></tr><tr><td>North Tanna</td><td>Use of bed netsClean hom... | <table><tr><td>Middle Bush</td><td>Use of bed netsClean homeTidy village/sourcereductionDrinking clean waterBlanket for protectionwhen sleeping duringtravel</td><td>Mostly seasonal use of bed netsPrimary motivation ismosquito nuiscanceNet rarely used whentravelling</td><td>Doctors & health officersCheif & church leader... |
bd3dea0d9151d634f3d2bc7fc2f5ad94f2b893e81fa845f640953d3c22e1b094.png | complex | <table><tr><td rowspan="3">Sex and variable</td><td colspan="4">Blood pressure category</td><td rowspan="3"><i>P</i> for difference<sup>b</sup></td></tr><tr><td>Normal</td><td>Pre-</td><td>Stage 1</td><td>Stage 2<sup>a</sup></td></tr><tr><td>Men</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> No. of... | <table><tr><td rowspan="3">Sex and variable</td><td colspan="4">Blood pressure category</td><td rowspan="3">P for differenceb</td></tr><tr><td>Normal</td><td>Pre-</td><td>Stage 1</td><td>Stage 2a</td></tr><tr><td colspan="4"></td></tr><tr><td>Men</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No. of part... | <table><tr><td>Smoking status, %</td><td></td><td></td><td></td><td></td><td><0.0001</td></tr><tr><td>Never</td><td>87.9</td><td>92.3</td><td>92.6</td><td>93.1</td><td></td></tr><tr><td>Former</td><td>2.3</td><td>1.7</td><td>1.5</td><td>1.7</td><td></td></tr><tr><td>Current</td><td>9.8</td><td>6.0</td><td>5.9</td><td>5... |
49b9650bad8a1b535d0e9feebfa90eae15e67eb5ef3d3a95237d7ccf441ba6c3.png | complex | <table><tr><td>Exon</td><td>Primers (3′-5′)</td><td>Annealing temperature (°C)</td><td>Buffer pH</td><td>MgCl<sub>2</sub> (mM)</td><td>% DMSO</td><td>Fragment (bp)</td></tr><tr><td rowspan="2">1</td><td>F: GCAGATTTAAAGCAACACCACC</td><td rowspan="2">60</td><td rowspan="2">8.4</td><td rowspan="2">1</td><... | <table><tr><td>Exon</td><td>Primers (3′-5′)</td><td>Annealing temperature (°C)</td><td>Buffer pH</td><td>MgCl2 (mM)</td><td>% DMSO</td><td>Fragment (bp)</td></tr><tr><td rowspan="2">1</td><td>F: GCAGATTTAAAGCAACACCACC</td><td rowspan="2">60</td><td rowspan="2">8.4</td><td rowspan="2">1</td><td rowspan="2">0</td><td row... | <table><tr><td rowspan="2">10</td><td>F: GCAATTTCACTATTCTATGAAAGG</td><td rowspan="2">52</td><td rowspan="2">8.4</td><td rowspan="2">1.5</td><td rowspan="2">0</td><td rowspan="2">348</td></tr><tr><td>R: ACAGAATTGGCTACATAATGGCT</td></tr></table> |
051f8ed7ad1e8f47a83c3eaa9357b3b585f044ec69007aff2db1708be6091c72.png | complex | <table><tr><td></td><td colspan="7"><i>r</i>/<i>P</i></td></tr><tr><td></td><td>sIL-6</td><td>sVEGF</td><td>pVEGF</td><td>D-D</td><td>Platelets</td><td>Fibrinogen</td><td>sVEGF/pl</td></tr><tr><td>sIL-6</td><td></td><td>0.25/0.03</td><td>0.33/0.005</td><td>0.41/0.006</td><td></td><td>0.23/0.06</td><td>0.22/0.06</td></t... | <table><tr><td></td><td colspan="7">r/P</td></tr><tr><td></td><td>sIL-6</td><td>sVEGF</td><td>pVEGF</td><td>D-D</td><td>Platelets</td><td>Fibrinogen</td><td>sVEGF/pl</td></tr><tr><td>sIL-6</td><td></td><td>0.25/0.03</td><td>0.33/0.005</td><td>0.41/0.006</td><td></td><td>0.23/0.06</td><td>0.22/0.06</td></tr><tr><td>sVEG... | <table><tr><td>VEGF</td><td></td><td></td><td></td><td>/0.0019</td><td>.05</td><td>26/0.0339</td><td>001</td></tr><tr><td>D-D</td><td></td><td></td><td></td><td></td><td></td><td>0.26/0.03</td><td>0.34/0.0061</td></tr></table> |
3b739a09abcdf520c305a4db641011f63646101ff8e0c41ff7bc36a3025ebcb3.png | complex | <table><tr><td colspan="2">Variable</td><td colspan="2">CTX only</td><td colspan="2">Trastuzumab + CTX</td><td colspan="2">Total</td><td><i>P</i>-value</td></tr><tr><td colspan="2">Number of patients</td><td colspan="2">45</td><td colspan="2">70</td><td colspan="2">115</td><td></td></tr><tr><td colspan="2">Gender</td><... | <table><tr><td colspan="2">Variable</td><td colspan="2">CTX only</td><td colspan="2">Trastuzumab + CTX</td><td colspan="2">Total</td><td>P-value</td></tr><tr><td colspan="2">Number of patients</td><td colspan="2">45</td><td colspan="2">70</td><td colspan="2">115</td><td></td></tr><tr><td colspan="2">Gender</td><td></td... | <table><tr><td colspan="2">Variable</td><td colspan="2">CTX only</td><td colspan="2">Trastuzumab + CTX</td><td colspan="2">Total</td><td>P-value</td></tr><tr><td></td><td>No</td><td>33</td><td>73.3%</td><td>52</td><td>74.3%</td><td>85</td><td>73.9%</td><td></td></tr><tr><td colspan="2">Underlying cardiac disease</td><t... |
43abd7ea9aa2958cb9c4c38f65bebf34e0d5086d9807b3466cc5c933a970d44f.png | simple | <table><tr><td>Factors</td><td>β</td><td>S.E.</td><td>aOR (95% CI)</td></tr><tr><td>Residence (rural vs. urban)</td><td>0.79</td><td>0.36</td><td>2.03 (1.30–4.25)</td></tr><tr><td>Parental history of T1DM (positive history vs. negative)</td><td>3.90</td><td>2.54</td><td>9.03 (1.02–85.32)</td></tr><tr><... | <table><tr><td>Factors</td><td>β</td><td>S.E.</td><td>aOR (95% CI)</td></tr><tr><td>Residence (rural vs. urban)</td><td>0.79</td><td>0.36</td><td>2.03 (1.30–4.25)</td></tr><tr><td>Parental history of T1DM (positive history vs. negative)</td><td>3.90</td><td>2.54</td><td>9.03 (1.02–85.32)</td></tr><tr><td>Mod Of Deliver... | <table><tr><td>Introduction of cows milk in first year of life (positive vs. negative)</td><td>2.99</td><td>0.42</td><td>19.94 (8.73–45.53)</td></tr><tr><td>Vitamin D Supplementation in first year of life (positive vs. negative)</td><td>−2.16</td><td>0.37</td><td>0.11 (0.05–0.24)</td></tr><tr><td>Physical Activity (hig... |
49045c228e57731c1c31b291eb285e94b24e524689c2ba5caf4ae261560c570e.png | simple | <table><tr><td>Sample sizes</td><td>N</td><td>Alternative</td><td>Power</td><td>Correct classif. rate</td></tr><tr><td>200/200/200/200</td><td>800</td><td>.05/.05/.05/.10</td><td>.682</td><td>.935</td></tr><tr><td>540/200/40/20</td><td>800</td><td>.05/.05/.05/.10</td><td><i>.251</i></td><td>.758</td></tr><tr><td>200/20... | <table><tr><td>Sample sizes</td></tr><tr><td>200/200/200/200</td></tr><tr><td>540/200/40/20</td></tr><tr><td>200/200/200/200</td></tr><tr><td>540/200/40/20</td></tr><tr><td>200/200/200/200</td></tr><tr><td>540/200/40/20</td></tr><tr><td>400/400/400/400</td></tr><tr><td>1340/200/40/20</td></tr><tr><td>400/400/400/400</t... | <table><tr><td>N</td><td>Alternative</td><td>Power</td><td>Correct classif. rate</td></tr><tr><td>800</td><td>.05/.05/.05/.10</td><td>.682</td><td>.935</td></tr><tr><td>800</td><td>.05/.05/.05/.10</td><td>.251</td><td>.758</td></tr><tr><td>800</td><td>.05/.05/.10/.10</td><td>.792</td><td>.831</td></tr><tr><td>800</td><... |
c17e26922501fa200748fe4a2fa0c28a05c9e57fac77e472e589420f038b0f2a.png | simple | <table><tr><td>Substance</td><td>Reported Usage</td><td>Percent of Survey Participants</td></tr><tr><td>Opioid Pharmaceuticals</td><td>18</td><td>5.95%</td></tr><tr><td>Hallucinogens</td><td>11</td><td>3.63%</td></tr><tr><td>MDMA/Ecstasy</td><td>10</td><td>3.30%</td></tr><tr><td>Cocaine/Crack Cocaine</td><td>7</td><td>... | <table><tr><td>Substance</td><td>Reported Usage</td><td>Percent of Survey Participants</td></tr><tr><td>Opioid Pharmaceuticals</td><td>18</td><td>5.95%</td></tr><tr><td>Hallucinogens</td><td>11</td><td>3.63%</td></tr><tr><td>MDMA/Ecstasy</td><td>10</td><td>3.30%</td></tr></table> | <table><tr><td>Cocaine/Crack Cocaine</td><td>7</td><td>2.31%</td></tr><tr><td>Benzodiazepine Pharmaceuticals</td><td>6</td><td>1.98%</td></tr><tr><td>Other Substances</td><td>5</td><td>1.65%</td></tr><tr><td>Stimulant Pharmaceuticals</td><td>3</td><td>0.99%</td></tr><tr><td>Methamphetamine</td><td>2</td><td>0.66%</td><... |
e4f94af152f9d28f7c7e4179400ba99cfceb42842d9bef13d2a362e34fcd6c20.png | complex | <table><tr><td>Variables</td><td>Lean</td><td>Overweight</td><td>Obese</td><td><i>p</i> for heterogeneity</td></tr><tr><td>BMI (kg/m<sup>2</sup>)(mean)</td><td>18.5–24.9922.7 ± 1.7</td><td>25–29.9927.1 ± 1.6</td><td>≥3033.5 ± 3.8</td><td></td></tr><tr><td>No. of subjects (%)</td><td>246... | <table><tr><td>Variables</td><td>Lean</td><td>Overweight</td><td>Obese</td><td>p for heterogeneity</td></tr><tr><td>BMI (kg/m2)(mean)</td><td>18.5–24.9922.7 ± 1.7</td><td>25–29.9927.1 ± 1.6</td><td>≥3033.5 ± 3.8</td><td></td></tr><tr><td>No. of subjects (%)</td><td>246 (51)</td><td>150 (31)</td><td>77 (18)</td><td></td... | <table><tr><td>Variables</td><td>Lean</td><td>Overweight</td><td>Obese</td><td>p for heterogeneity</td></tr><tr><td>Myocardial infarction</td><td>1</td><td>3</td><td>1</td><td>0.3</td></tr><tr><td>Cancer</td><td>11</td><td>6</td><td>9</td><td>0.03</td></tr><tr><td>Diabetes</td><td>3</td><td>6</td><td>9</td><td><0.0001<... |
513e2705eb476525540ba7d2362d3caebe6c5db6dda6115897e9f5d1bb1797eb.png | simple | <table><tr><td>Time since quitting</td><td>Beneficial health changes that take place</td></tr><tr><td>24 h</td><td>Lungs start to clear out mucus and other smoking debris</td></tr><tr><td>48 h</td><td>Carbon monoxide will be eliminated from the body. Ability to taste and smell is greatly improved</td></tr><tr><td>72 h<... | <table><tr><td>Time since quitting</td></tr><tr><td>24 h</td></tr><tr><td>48 h</td></tr><tr><td>72 h</td></tr><tr><td>2–12 weeks</td></tr><tr><td>3–9 months</td></tr><tr><td>1 year</td></tr><tr><td>10 years</td></tr><tr><td>15 years</td></tr></table> | <table><tr><td>Beneficial health changes that take place</td></tr><tr><td>Lungs start to clear out mucus and other smoking debris</td></tr><tr><td>Carbon monoxide will be eliminated from the body. Ability to taste and smell is greatly improved</td></tr><tr><td>Breathing becomes easier. Bronchial tubes begin to relax an... |
2b728e94b64c77e8c57028284c2154b77100046446a0aa03874716903639008a.png | simple | <table><tr><td><i>Characteristic</i></td><td><i>N</i></td><td><i>%</i></td></tr><tr><td>Pre-pregnancy nutritional status (BMI)</td><td></td><td></td></tr><tr><td>Underweight (<18.5 kg/m<sup>2</sup>)</td><td>84</td><td>10.9</td></tr><tr><td>Normal weight (18.5 – 24.99 kg/m<sup>2</sup>)</td><td>494</td><td>63.8<... | <table><tr><td>Characteristic</td><td>N</td><td>%</td></tr><tr><td>Pre-pregnancy nutritional status (BMI)</td><td></td><td></td></tr><tr><td>Underweight (<18.5 kg/m2)</td><td>84</td><td>10.9</td></tr><tr><td>Normal weight (18.5 – 24.99 kg/m2)</td><td>494</td><td>63.8</td></tr><tr><td>Overweight (25.0 – 29.99 kg/m2)</td... | <table><tr><td>ormal</td><td>88</td><td>.6</td></tr><tr><td>Forceps</td><td>22</td><td>3.8</td></tr><tr><td>Cesarean section</td><td>270</td><td>46.6</td></tr><tr><td>Gestational age at birth</td><td></td><td></td></tr><tr><td>Preterm (<37 weeks)</td><td>26</td><td>4.7</td></tr><tr><td>Term (≥37 weeks)</td><td>527</td>... |
7cab41ad43ea6d49f724014d02eab406d283381d41fc557db2e634517e5d3a7b.png | simple | <table><tr><td>Analysis</td><td>Number of plants assayed</td><td>Number of tolerant plants</td><td>Transformation frequency</td></tr><tr><td>Basta leaf paint</td><td>78</td><td>70</td><td>89.73%</td></tr><tr><td>Kanamycin/paromomycin Leaf bleach</td><td>34</td><td>32</td><td>94.12%</td></tr></table> | <table><tr><td>Analysis</td><td>Number of plants assayed</td><td>Number of tolerant plants</td><td>Transformation frequency</td></tr></table> | <table><tr><td>Basta leaf paint</td><td>78</td><td>70</td><td>89.73%</td></tr><tr><td>Kanamycin/paromomycin Leaf bleach</td><td>34</td><td>32</td><td>94.12%</td></tr></table> |
9041d001108cdf6f3abad0897d6840b9c7e47351597d5b03df2850fa28544111.png | simple | <table><tr><td>Plant specie</td><td> Aa length</td><td>PTS1</td><td>pI</td><td>Molecular Mass (kDa)</td><td>Accession number</td></tr><tr><td><i>Arabidopsis thaliana</i></td><td>486</td><td>-SKI</td><td>7.02 </td><td>53.6</td><td>AEE73797.1</td></tr><tr><td><i>Cleome spinosa</i></td><td>485</td><td>-SMI</td><td>5.80</t... | <table><tr><td>Plant specie</td><td>Aa length</td><td>PTS1</td><td>pI</td><td>Molecular Mass (kDa)</td><td>Accession number</td></tr><tr><td>Arabidopsis thaliana</td><td>486</td><td>-SKI</td><td>7.02</td><td>53.6</td><td>AEE73797.1</td></tr><tr><td>Cleome spinosa</td><td>485</td><td>-SMI</td><td>5.80</td><td>53.6</td><... | <table><tr><td>Plant specie</td><td>Aa length</td><td>PTS1</td><td>pI</td><td>Molecular Mass (kDa)</td><td>Accession number</td></tr><tr><td>Vitis vinifera</td><td>438</td><td>-SKI</td><td>8.13</td><td>48.3</td><td>CAN67602.1</td></tr><tr><td>Zea mays</td><td>480</td><td>-SKI</td><td>6.09</td><td>52.7</td><td>ACN35899.... |
70d62af37847142c49bb710b344006c1ac1f791da70b43ed69c15e35ee9b85ab.png | complex | <table><tr><td>Oil</td><td>Isothermal T (°C)</td><td>t<sub>0</sub> (min)</td><td>t<sub>max</sub>(min)</td><td>Regression equation<sub>a</sub></td><td>R<sup>2</sup><sub>b</sub></td><td>Reported t<sub>0</sub> or shelf life at 20 °C (d)</td></tr><tr><td colspan="7">Linola</td></tr><tr><td></td><td>100</td><td>17... | <table><tr><td>Oil</td><td>Isothermal T (°C)</td><td>t0 (min)</td><td>tmax(min)</td><td>Regression equationa</td><td>R2b</td><td>Reported t0 or shelf life at 20 °C (d)</td></tr><tr><td colspan="7">Linola</td></tr><tr><td></td><td>100</td><td>170.7</td><td>287.1</td><td rowspan="3">Log (k) = 0.0211 T-4.3479</td><td rows... | <table><tr><td colspan="7">GT</td></tr><tr><td></td><td>100</td><td>162.5</td><td>229.9</td><td rowspan="3">Log (k) = 0.0237 T – 4.5500</td><td rowspan="3">0.9633</td><td rowspan="3">8.3</td></tr><tr><td></td><td>110</td><td>78.4</td><td>128.4</td></tr><tr><td></td><td>120</td><td>54.6</td><td>88.4</td></tr><tr><td col... |
bfd119c0b6be480ddb5b805cebdf7ac9bb286ca5b70f3b62c8c2139a08db1fff.png | simple | <table><tr><td>Resource</td><td>Brief description</td><td>Included information</td></tr><tr><td>Facilitator manual</td><td>Comprehensive train-the-trainer manual detailing all information required for the delivery of the program</td><td>* Introduction* Successful facilitating* Background to the research* Session guides... | <table><tr><td>Resource</td><td>Brief description</td><td>Included information</td></tr><tr><td>Facilitator manual</td><td>Comprehensive train-the-trainer manual detailing all information required for the delivery of the program</td><td>* Introduction* Successful facilitating* Background to the research* Session guides... | <table><tr><td>Kid's Handbook</td><td>Includes tasks for children to complete each week with their dads that must be signed off with their dads (space to receive a sticker from facilitators if completed)</td><td>* Kids homework activities* Recipes to cook with dad</td></tr><tr><td>Green slips</td><td>Homework activity ... |
67c8cf325ee2bc68262aa7b706ce6888a914cb6ccbc32573867218eda4a3a3fd.png | simple | <table><tr><td></td><td>F0-1</td><td>F2-4</td><td>P value</td><td>F0-2</td><td>F3-4</td><td>P value</td><td>F0-3</td><td>F4</td><td>P value</td></tr><tr><td>HBeAg (+)</td><td>4.60 (4.38-4.78)</td><td>4.12 (3.98-4.30)</td><td><0.001</td><td>4.51 (4.28-4.74)</td><td>4.03 (3.89-4.25)</td><td><0.001</td><td>4.48 (4.2... | <table><tr><td></td><td>F0-1</td><td>F2-4</td></tr><tr><td>HBeAg (+)</td><td>4.60 (4.38-4.78)</td><td>4.12 (3.98-4.30)</td></tr><tr><td>HBeAg (-)</td><td>3.20 (2.77-3.62)</td><td>3.42 (2.84-3.83)</td></tr></table> | <table><tr><td>P value</td><td>F0-2</td><td>F3-4</td><td>P value</td><td>F0-3</td><td>F4</td><td>P value</td></tr><tr><td><0.001</td><td>4.51 (4.28-4.74)</td><td>4.03 (3.89-4.25)</td><td><0.001</td><td>4.48 (4.26-4.71)</td><td>3.95 (3.74-4.10)</td><td><0.001</td></tr><tr><td>0.084</td><td>3.32 (2.82-3.82)</td><td>3.24 ... |
4e880de69aab207044031f62ef14f6d0d4c16c6e6daac698ab85bced4f24f56e.png | complex | <table><tr><td></td><td></td><td colspan="3">Echium Oil</td><td colspan="3">Fish Oil</td><td colspan="3">Significant Effect</td></tr><tr><td>Fatty Acids</td><td>Control</td><td>EO-1</td><td>EO-3</td><td>EO-5</td><td>FO-1</td><td>FO-3</td><td>FO-5</td><td>Oil</td><td>Dose</td><td>Oil × Dose</td></tr><tr><td>C16:0</... | <table><tr><td></td><td></td><td colspan="3">Echium Oil</td><td colspan="3">Fish Oil</td><td colspan="3">Significant Effect</td></tr><tr><td>Fatty Acids</td><td>Control</td><td>EO-1</td><td>EO-3</td><td>EO-5</td><td>FO-1</td><td>FO-3</td><td>FO-5</td><td>Oil</td><td>Dose</td><td>Oil × Dose</td></tr><tr><td>C16:0</td><t... | <table><tr><td></td><td></td><td colspan="3">Echium Oil</td><td colspan="3">Fish Oil</td><td colspan="3">Significant Effect</td></tr><tr><td>Fatty Acids</td><td>Control</td><td>EO-1</td><td>EO-3</td><td>EO-5</td><td>FO-1</td><td>FO-3</td><td>FO-5</td><td>Oil</td><td>Dose</td><td>Oil × Dose</td></tr><tr><td>Total n-3 PU... |
77b0561c4a86b6b8f1da0143197e99c6f158f8c5267f351916f894f198c2cfe4.png | complex | <table><tr><td rowspan="2">Stimulus/Cytokine</td><td>Model 1</td><td>Model 2</td><td>Model 3</td></tr><tr><td>OR (95%CI)</td><td>OR (95%CI)</td><td>OR (95%CI)</td></tr><tr><td>Spontaneous production</td><td></td><td></td><td></td></tr><tr><td> IL-5 (n = 418)</td><td>1.42 (0.93;2.15)</td><td>1.00 (0.52;1.92)</td><td>0.9... | <table><tr><td rowspan="2">Stimulus/Cytokine</td><td>Model 1</td><td>Model 2</td><td>Model 3</td></tr><tr><td>OR (95%CI)</td><td>OR (95%CI)</td><td>OR (95%CI)</td></tr><tr><td>Spontaneous production</td><td></td><td></td><td></td></tr><tr><td>IL-5 (n = 418)</td><td>1.42 (0.93;2.15)</td><td>1.00 (0.52;1.92)</td><td>0.95... | <table><tr><td>IL-10 (n = 416)</td><td>2.42 (1.54;3.78)</td><td>1.83 (0.91;3.68)</td><td>2.24 (1.07;4.70)</td></tr><tr><td>IL-17 (n = 411)</td><td>1.22 (0.57;2.61)</td><td>1.63 (0.61;4.38)</td><td>1.63 (0.57;4.67)</td></tr></table> |
b196ffaa06b07e309127b22edb8bbaca8e6ff96d22e08a94ba25beffbb1d77e7.png | complex | <table><tr><td> </td><td>Kindergarten</td><td>Elementary school</td><td>Junior high school</td><td rowspan="3"><i>P</i>-value<sup>b</sup></td></tr><tr><td> </td><td><i>n</i> (%)</td><td><i>n</i> (%)</td><td><i>n</i> (%)</td></tr><tr><td colspan="4">Feeling upon awakening</td><td> </td></tr><tr><td> good</td><td>213 (86... | <table><tr><td></td><td>Kindergarten</td><td>Elementary school</td><td>Junior high school</td><td rowspan="3">P-valueb</td></tr><tr><td></td><td>n (%)</td><td>n (%)</td><td>n (%)</td></tr><tr><td colspan="4"></td></tr><tr><td colspan="4">Feeling upon awakening</td><td></td></tr></table> | <table><tr><td>good</td><td>213 (86.2)</td><td>877 (76.5)</td><td>389 (61.6)</td><td></td></tr><tr><td>bad</td><td>34 (13.8)</td><td>270 (23.5)</td><td>243 (38.5)</td><td></td></tr><tr><td>total</td><td>247</td><td>1147</td><td>632</td><td><0.01</td></tr><tr><td colspan="4">Time of awakening</td><td></td></tr><tr><td><... |
355f5bf7dc943e1f4e693e5e9b39195b3269526e70386ed6dfbf1946f4380d5e.png | complex | <table><tr><td>Instrument</td><td>Countries</td></tr><tr><td colspan="2">Supply side regulation: in patent drugs</td></tr><tr><td>Price controls: administrative or statutory pricing</td><td>All EU Member States except Germany, UK and, to a certain extent, Sweden</td></tr><tr><td>External reference pricing</td><td>All E... | <table><tr><td>Instrument</td><td>Countries</td></tr><tr><td colspan="2">Supply side regulation: in patent drugs</td></tr><tr><td>Price controls: administrative or statutory pricing</td><td>All EU Member States except Germany, UK and, to a certain extent, Sweden</td></tr><tr><td>External reference pricing</td><td>All E... | <table><tr><td>Instrument</td><td>Countries</td></tr><tr><td>Prescription monitoring and audit</td><td>Belgium, UK, Netherlands, France, Denmark, Sweden, Estonia</td></tr><tr><td colspan="2">Demand side regulation: policies towards pharmacies</td></tr><tr><td>Control of remuneration (e.g. margins, fees) including contr... |
994e7fed73a981166042137eb1ceb3ccf34538781ff06c62ab1192a1de65d163.png | complex | <table><tr><td> </td><td colspan="3">Baseline</td><td colspan="3">12 months</td><td colspan="3">18 months</td></tr><tr><td> </td><td>W</td><td>WB</td><td>C</td><td>W</td><td>WB</td><td>C</td><td>W</td><td>WB</td><td>C</td></tr><tr><td> </td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td... | <table><tr><td></td><td colspan="3">Baseline</td><td colspan="3">12 months</td><td colspan="3">18 months</td></tr></table> | <table><tr><td></td><td>W</td><td>WB</td><td>C</td><td>W</td><td>WB</td><td>C</td><td>W</td><td>WB</td><td>C</td></tr><tr><td></td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td><td>N</td></tr><tr><td>Variables</td><td>Mean±SD</td><td>Mean±SD</td><td>Mean±SD</td><td>Mean±SD</td><td>Mean... |
aabae43c2e062a4e91f4301d8d7608f69ad4601a63e5ee4647388d35db29c119.png | complex | <table><tr><td></td><td></td><td colspan="4">Male</td><td colspan="4">Female</td></tr><tr><td></td><td></td><td colspan="2">CCU or ICU</td><td colspan="2">Medical ward</td><td colspan="2">CCU or ICU</td><td colspan="2">Medical ward</td></tr><tr><td>Age groups</td><td>Standard Population</td><td>Death rate %</td><td>Exp... | <table><tr><td></td><td></td><td colspan="4">Male</td><td colspan="4">Female</td></tr><tr><td></td><td></td><td colspan="2">CCU or ICU</td><td colspan="2">Medical ward</td><td colspan="2">CCU or ICU</td><td colspan="2">Medical ward</td></tr><tr><td>Age groups</td><td>Standard Population</td><td>Death rate %</td><td>Exp... | <table><tr><td>6–78</td><td>9</td><td>2.77</td><td>5.7</td><td>65</td><td>47.0</td><td>.95</td><td>8.0</td><td>7</td><td>.2</td></tr><tr><td>79 +</td><td>1102</td><td>5.80</td><td>63.9</td><td>6.67</td><td>73.5</td><td>7.08</td><td>78.0</td><td>12.03</td><td>132.6</td></tr><tr><td colspan="2">Total number of deaths exp... |
7cb6bcd64c0d923dbf16dab46e8843b522d327754a546daa30e819ec78c1dc58.png | simple | <table><tr><td>ATC Code</td><td>Drug classification</td><td>No. of visits </td><td>%</td></tr><tr><td>G01A</td><td>Anti-infectives</td><td>5402</td><td>15.1%</td></tr><tr><td>M01A</td><td>Anti-inflammatory, non-steroids</td><td>3754 </td><td>10.5%</td></tr><tr><td>N02B</td><td>Other analgesics and anti-pyretics</td><td... | <table><tr><td>ATC Code</td><td>Drug classification</td></tr><tr><td>G01A</td><td>Anti-infectives</td></tr><tr><td>M01A</td><td>Anti-inflammatory, non-steroids</td></tr><tr><td>N02B</td><td>Other analgesics and anti-pyretics</td></tr><tr><td>G03D</td><td>Progestogens</td></tr><tr><td>A02A</td><td>Antacids</td></tr><tr>... | <table><tr><td>No. of visits</td><td>%</td></tr><tr><td>5402</td><td>15.1%</td></tr><tr><td>3754</td><td>10.5%</td></tr><tr><td>2884</td><td>8.1%</td></tr><tr><td>2871</td><td>8.0%</td></tr><tr><td>2683</td><td>7.5%</td></tr><tr><td>2090</td><td>5.9%</td></tr><tr><td>1932</td><td>5.4%</td></tr><tr><td>1866</td><td>5.2%... |
d359cf6779ec4a62b83fef499338d02626981798ccde74e4b76d13b1e95d4aa0.png | simple | <table><tr><td>Variables</td><td>Number</td><td>Percentage </td></tr><tr><td>Acute or chronic inflammation</td><td>36</td><td>30</td></tr><tr><td>Rheumatism </td><td>33</td><td>26.6</td></tr><tr><td>Degeneration of valves</td><td>49</td><td>40.8</td></tr><tr><td>Endocarditic </td><td>2</td><td>1.6</td></tr></table> | <table><tr><td>Variabl</td><td>Numbe</td><td>Percen</td></tr></table> | <table><tr><td>es</td><td>r</td><td>tage</td></tr><tr><td>Acute or chronic inflammation</td><td>36</td><td>30</td></tr><tr><td>Rheumatism</td><td>33</td><td>26.6</td></tr><tr><td>Degeneration of valves</td><td>49</td><td>40.8</td></tr><tr><td>Endocarditic</td><td>2</td><td>1.6</td></tr></table> |
894cd54dc033248001c560a56c6dbc378e474eaf04bd682ad11adf166f34a660.png | complex | <table><tr><td></td><td></td><td colspan="3">Pairwise correlation at age 7 year</td></tr><tr><td>Compound</td><td>PFAS concentration, ng/mL, median (IQR<sup>a</sup>)</td><td>PFOS</td><td>PFOA</td><td>PFHxS</td></tr><tr><td>Age 5 year</td><td></td><td></td><td></td><td></td></tr><tr><td>PFOS</td><td>17.3 (14.2,21.3)</td... | <table><tr><td></td><td></td><td colspan="3">Pairwise correlation at age 7 year</td></tr><tr><td>Compound</td><td>PFAS concentration, ng/mL, median (IQRa)</td><td>PFOS</td><td>PFOA</td><td>PFHxS</td></tr><tr><td>Age 5 year</td><td></td><td></td><td></td><td></td></tr></table> | <table><tr><td></td><td></td><td colspan="3">Pairwise correlation at age 7 year</td></tr><tr><td>Compound</td><td>PFAS concentration, ng/mL, median (IQRa)</td><td>PFOS</td><td>PFOA</td><td>PFHxS</td></tr><tr><td>PFOS</td><td>17.3 (14.2,21.3)</td><td>0.77</td><td>0.06</td><td>0.43</td></tr><tr><td>PFOA</td><td>4.1 (3.3,... |
5b13e3946e7db79e1ab6827d2ac096aacf3582858a3e6d3728afedd2692bf47e.png | simple | <table><tr><td>Analyses</td><td>Nanoemulsion</td><td>Curcumin-nanoemulsion</td></tr><tr><td>Size (nm)</td><td>200 ± 9.9</td><td>199 ± 0.2</td></tr><tr><td>Zeta potential (mV)</td><td>−40.2</td><td>−46.3</td></tr><tr><td>Polydispersity index (PdI)</td><td>0.248</td><td>0.179</td></tr></table> | <table><tr><td>Analyses</td><td>Nanoemulsion</td><td>Curcumin-nanoemulsion</td></tr><tr><td>Size (nm)</td><td>200 ± 9.9</td><td>199 ± 0.2</td></tr></table> | <table><tr><td>Analyses</td><td>Nanoemulsion</td><td>Curcumin-nanoemulsion</td></tr><tr><td>Zeta potential (mV)</td><td>−40.2</td><td>−46.3</td></tr><tr><td>Polydispersity index (PdI)</td><td>0.248</td><td>0.179</td></tr></table> |
cd1cfe32c43d6206340212aecb87519938e1fdb3931f5763bebc34979ab86378.png | simple | <table><tr><td></td><td>BMD (g/cm<sup>2)</sup></td><td>BMC (g)</td><td>Area (cm<sup>2)</sup></td></tr><tr><td>Lumbar Vertebra</td><td></td><td></td><td></td></tr><tr><td> Baseline (n = 8)</td><td>0.237 ± 0.018</td><td>0.502 ± 0.073</td><td>2.124 ± 0.287</td></tr><tr><td> Control (n = 12)</td><td>0.259 &#... | <table><tr><td></td><td>BMD (g/cm2)</td><td>BMC (g)</td><td>Area (cm2)</td></tr><tr><td>Lumbar Vertebra</td><td></td><td></td><td></td></tr><tr><td>Baseline (n = 8)</td><td>0.237 ± 0.018</td><td>0.502 ± 0.073</td><td>2.124 ± 0.287</td></tr><tr><td>Control (n = 12)</td><td>0.259 ± 0.026</td><td>0.609 ± 0.107</td><td>2.3... | <table><tr><td></td><td>BMD (g/cm2)</td><td>BMC (g)</td><td>Area (cm2)</td></tr><tr><td>Control (n = 12)</td><td>0.323 ± 0.068</td><td>0.258 ± 0.052</td><td>0.794 ± 0.058</td></tr><tr><td>1.5 mg CsA (n = 11)</td><td>0.311 ± 0.066</td><td>0.241 ± 0.058</td><td>0.771 ± 0.052</td></tr><tr><td>7.5 mg CsA (n = 9)</td><td>0.... |
7eb352bb9b7058be31025a521a60981a1412827629c03d651783f2e2ada4a3ae.png | simple | <table><tr><td>Indicators</td><td>Value</td></tr><tr><td>White blood cell</td><td>5200/<i>μ</i>L</td></tr><tr><td>Hemoglobin</td><td>11.3 g/dL</td></tr><tr><td>Platelet</td><td>103 × 10<sup>3</sup>/<i>μ</i>L</td></tr><tr><td>Prothrombin time</td><td>96%</td></tr><tr><td>Activated partial thromboplastin t... | <table><tr><td>Indicators</td></tr><tr><td>White blood cell</td></tr><tr><td>Hemoglobin</td></tr><tr><td>Platelet</td></tr><tr><td>Prothrombin time</td></tr><tr><td>Activated partial thromboplastin time</td></tr><tr><td>Aspartate aminotransferase</td></tr><tr><td>Alanine aminotransferase</td></tr><tr><td>Lactate dehydr... | <table><tr><td>Value</td></tr><tr><td>5200/μL</td></tr><tr><td>11.3 g/dL</td></tr><tr><td>103 × 103/μL</td></tr><tr><td>96%</td></tr><tr><td>22.6 s</td></tr><tr><td>26 U/L</td></tr><tr><td>20 U/L</td></tr><tr><td>244 U/L</td></tr><tr><td>280 U/L</td></tr><tr><td>0.7 mg/dL</td></tr><tr><td>6.9 g/dL</td></tr><tr><td>3.9 ... |
dcfd7677c0181f651175ed12a59de2c5588fb07ac1d7698028648e1ebe019ccc.png | complex | <table><tr><td>H-reflex parameters</td><td>Ankle Positions</td><td colspan="6">Muscle and posture</td></tr><tr><td></td><td></td><td colspan="2">Sol</td><td colspan="2">MG</td><td colspan="2">LG</td></tr><tr><td></td><td></td><td>Lying</td><td>Standing</td><td>Lying</td><td>Standing</td><td>Lying</td><td>Standing</td><... | <table><tr><td>H-reflex parameters</td><td>Ankle Positions</td><td colspan="6">Muscle and posture</td></tr><tr><td></td><td></td><td colspan="2">Sol</td><td colspan="2">MG</td><td colspan="2">LG</td></tr><tr><td></td><td></td><td>Lying</td><td>Standing</td><td>Lying</td><td>Standing</td><td>Lying</td><td>Standing</td><... | <table><tr><td></td><td></td><td>47†(2.63)</td><td>96§(2.18)</td><td>)</td><td>§(0.60)</td><td>0.34)</td><td>49§(0.51)</td></tr><tr><td></td><td>PF</td><td>5.95(3.37)</td><td>6.40‡(2.88)</td><td>1.76(1.19)</td><td>2.65‡(1.52)</td><td>1.38(0.89)</td><td>1.81‡(0.97)</td></tr><tr><td>H/M</td><td>N</td><td>0.51*†(0.17)</td... |
76dc40985f8fc0941018d5f09099dafb577510518ae4bf7e6a49aa41dfa726b9.png | simple | <table><tr><td>Groups</td><td>LDH</td><td>CK-MB</td><td>CK</td><td>CTN-I</td><td>MB</td></tr><tr><td>C</td><td>0.92 ± 0.04</td><td>2.11 ± 0.18</td><td>11.70 ± 0.46</td><td>144.61 ± 12.71</td><td>3.32 ± 0.49</td></tr><tr><td>EE</td><td>1.08 ± 0.09<sup><i>∗</i></sup></td><td>3.23 ±... | <table><tr><td>Groups</td><td>LDH</td><td>CK-MB</td><td>CK</td><td>CTN-I</td><td>MB</td></tr><tr><td>C</td><td>0.92 ± 0.04</td><td>2.11 ± 0.18</td><td>11.70 ± 0.46</td><td>144.61 ± 12.71</td><td>3.32 ± 0.49</td></tr><tr><td>EE</td><td>1.08 ± 0.09∗</td><td>3.23 ± 0.19∗</td><td>16.93 ± 0.41∗</td><td>172.00 ± 12.83∗</td><... | <table><tr><td>Groups</td><td>LDH</td><td>CK-MB</td><td>CK</td><td>CTN-I</td><td>MB</td></tr><tr><td>HS</td><td>1.02 ± 0.10#</td><td>2.57 ± 0.21#Δ</td><td>13.19 ± 1.91#Δ</td><td>159.26 ± 8.93</td><td>3.98 ± 0.54#Δ</td></tr></table> |
8516d483d2d2f11c25f4d5844c3722e908cbdd4b0fca508607e268a5769ec1a1.png | complex | <table><tr><td>Genotypes</td><td colspan="3">No. identified proteins</td><td colspan="3">ρ-Value<sup>a</sup>/FPR<sup>b</sup>(%)</td><td>No. proteins</td></tr><tr><td></td><td>Rep#1</td><td>Rep#2</td><td>Rep#3</td><td>Rep#1</td><td>Rep#2</td><td>Rep#3</td><td></td></tr><tr><td>Resistant<sup>c</sup></td><td>3297</td... | <table><tr><td>Genotypes</td><td colspan="3">No. identified proteins</td><td colspan="3">ρ-Valuea/FPRb(%)</td><td>No. proteins</td></tr></table> | <table><tr><td></td><td>Rep#1</td><td>Rep#2</td><td>Rep#3</td><td>Rep#1</td><td>Rep#2</td><td>Rep#3</td><td></td></tr><tr><td>Resistantc</td><td>3297</td><td>3302</td><td>3602</td><td>93/0.71</td><td>92/0.70</td><td>93/0.70</td><td>2002</td></tr><tr><td>Susceptiblec</td><td>3228</td><td>3187</td><td>3153</td><td>93/0.7... |
c55dcde3a3f959f6751fc1b756a3190eccdfee801a430c12daf31b820acb6806.png | simple | <table><tr><td>Key actor</td><td>Moura-Barrancos</td><td>Guadiana</td><td>Malcata</td><td>Total</td></tr><tr><td>Land owners (including livestock breeders)</td><td>9</td><td>9</td><td>5</td><td>23</td></tr><tr><td>Local council representatives</td><td>8</td><td>8</td><td>8</td><td>24</td></tr><tr><td>Local nature conse... | <table><tr><td>Key actor</td><td>Moura-Barrancos</td><td>Guadiana</td><td>Malcata</td><td>Total</td></tr><tr><td>Land owners (including livestock breeders)</td><td>9</td><td>9</td><td>5</td><td>23</td></tr><tr><td>Local council representatives</td><td>8</td><td>8</td><td>8</td><td>24</td></tr><tr><td>Local nature conse... | <table><tr><td>Key actor</td><td>Moura-Barrancos</td><td>Guadiana</td><td>Malcata</td><td>Total</td></tr><tr><td>Total</td><td></td><td></td><td></td><td>131</td></tr><tr><td>Hunter</td><td>26</td><td>19</td><td>15</td><td>60</td></tr><tr><td>Non-hunter</td><td>26</td><td>23</td><td>22</td><td>71</td></tr></table> |
8967f96dbb8410715325620c49fc323a70de9fa327f43c2946d050080c4d7b76.png | complex | <table><tr><td> </td><td colspan="2"> Participants</td><td colspan="2">GPS routes</td></tr><tr><td> </td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td>Total/All</td><td>175</td><td> </td><td>1191</td><td> </td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Girl</td><td>89</td><td>50.8... | <table><tr><td></td><td colspan="2">Participants</td><td colspan="2">GPS routes</td></tr><tr><td></td><td>N</td><td>%</td><td>N</td><td>%</td></tr><tr><td>Total/All</td><td>175</td><td></td><td>1191</td><td></td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td></tr><tr><td>Girl</td><td>89</td><td>50.86%</td><td... | <table><tr><td>Over £50,000 to £70,000</td><td>30</td><td>17.14%</td><td>184</td><td>15.45%</td></tr><tr><td>Over £70,000</td><td>10</td><td>5.71%</td><td>78</td><td>6.55%</td></tr><tr><td>I do not wish to share this information</td><td>28</td><td>16.00%</td><td>203</td><td>17.04%</td></tr></table> |
3674f0e61e6f81351688d6d71fd17c478cef1b0f98477b6af47c3a61abc0e49c.png | complex | <table><tr><td rowspan="2">Measurement day</td><td rowspan="2">Dosage</td><td colspan="2">ucOC (ng/mL)</td><td colspan="2">Gla-OC (ng/mL)</td><td colspan="2">UGR</td><td colspan="2">Dietary vitamin K intake (μg/week)</td></tr><tr><td>Median</td><td>Range</td><td>Median</td><td>Range</td><td>Median</td><td>Range</t... | <table><tr><td rowspan="2">Measurement day</td><td rowspan="2">Dosage</td><td colspan="2">ucOC (ng/mL)</td><td colspan="2">Gla-OC (ng/mL)</td><td colspan="2">UGR</td><td colspan="2">Dietary vitamin K intake (μg/week)</td></tr><tr><td>Median</td><td>Range</td><td>Median</td><td>Range</td><td>Median</td><td>Range</td><td... | <table><tr><td>Day 29</td><td>900 μg/day</td><td>2.98</td><td>(1.27-6.90)**</td><td>22.75</td><td>(12.38-38.10)*</td><td>0.15</td><td>(0.10-0.23)**</td><td>9.60</td><td>(0.00-196.94)</td></tr><tr><td>Day 36</td><td>1500 μg/day</td><td>3.92</td><td>(1.88-7.52)*</td><td>23.33</td><td>(13.97-45.49)**</td><td>0.15</td><td>... |
cb284a639c0aeed84de90a360cfbe35af8509436da56f951aa5115cae125acd4.png | simple | <table><tr><td>Topic</td><td>Reference</td><td>Question</td><td>Summary of the results</td></tr><tr><td>Knowledge</td><td>(26–42)</td><td>Differences in knowledge</td><td>Almost all studies found a gradient in knowledge about HPV and cervical cancer with any of the variables used to measure SES or deprivation: ed... | <table><tr><td>Topic</td><td>Reference</td><td>Question</td><td>Summary of the results</td></tr><tr><td>Knowledge</td><td>(26–42)</td><td>Differences in knowledge</td><td>Almost all studies found a gradient in knowledge about HPV and cervical cancer with any of the variables used to measure SES or deprivation: educatio... | <table><tr><td>Coverage</td><td>(16, 49–51)</td><td>Longer screening intervals can increase the coverage for hard-to-reach population</td><td>No data are available</td></tr><tr><td></td><td>(9, 52)</td><td>Access to opportunistic HPV testing could be limited by the high cost of the test in private laboratories</td><td>... |
797e12826203697a09d4590807cc41abe01757656ed803f9f0ac5bd84da080e4.png | simple | <table><tr><td><i>Cytogenetic abnormality</i></td><td><i>Frequency</i></td><td>ASXL1 <i>mutational frequency</i></td><td>SETBP1 <i>mutational frequency</i></td><td>SRSF2 <i>mutational frequency</i></td><td>U2AF1 <i>mutational frequency</i></td><td>SF3B1 <i>mutational frequency</i></td><td><i>Spanish cytogenetic risk st... | <table><tr><td>Cytogenetic abnormality</td><td>Frequency</td><td>ASXL1 mutational frequency</td><td>SETBP1 mutational frequency</td><td>SRSF2 mutational frequency</td><td>U2AF1 mutational frequency</td><td>SF3B1 mutational frequency</td><td>Spanish cytogenetic risk stratification</td><td>Mayo–French cytogenetic risk st... | <table><tr><td>Cytogenetic abnormality</td><td>Frequency</td><td>ASXL1 mutational frequency</td><td>SETBP1 mutational frequency</td><td>SRSF2 mutational frequency</td><td>U2AF1 mutational frequency</td><td>SF3B1 mutational frequency</td><td>Spanish cytogenetic risk stratification</td><td>Mayo–French cytogenetic risk st... |
02cb4251e0872e38a50aefba503cdeb163749621e5fc64bbd52c82912fee4424.png | simple | <table><tr><td>Risk factor</td><td>Changes in capillary morphology or blood rheology</td></tr><tr><td>Aging</td><td>Human brain: Pericyte loss. Variable capillary diameters, increased capillary tortuosity, twisting, and looping. Thickened basement membranes with inclusions. Pericapillary fibrosis [29, 30]</td></tr><tr>... | <table><tr><td>Risk factor</td><td>Changes in capillary morphology or blood rheology</td></tr><tr><td>Aging</td><td>Human brain: Pericyte loss. Variable capillary diameters, increased capillary tortuosity, twisting, and looping. Thickened basement membranes with inclusions. Pericapillary fibrosis [29, 30]</td></tr></ta... | <table><tr><td>Risk factor</td><td>Changes in capillary morphology or blood rheology</td></tr><tr><td>Hypertension</td><td>Animal brain: Pericyte degeneration, swelling of endothelium and surrounding astrocyte end feet. Thickened basement membranes [31, 32]In vitro: Angiotensin II, endothelin-1 constrict retinal pericy... |
315ef80ab1b1dbdf332c36eaea4dc76b86ad03cfdb50fbeec50af2b62493fcc1.png | simple | <table><tr><td>Authors</td><td>Contrast</td></tr><tr><td><sup>*</sup>Aichorn et al., 2009</td><td>False belief > photo (question)</td></tr><tr><td><sup>*</sup>Abraham et al., 2010</td><td>Belief-questions > control-questions and desire-questions > control-questions</td></tr><tr><td><sup>*</sup>Bahnemann et al.... | <table><tr><td>Authors</td><td>Contrast</td></tr><tr><td>*Aichorn et al., 2009</td><td>False belief > photo (question)</td></tr><tr><td>*Abraham et al., 2010</td><td>Belief-questions > control-questions and desire-questions > control-questions</td></tr><tr><td>*Bahnemann et al., 2010</td><td>ToM judgments minus appeara... | <table><tr><td>Young et al., 2007</td><td>Belief minus photo</td></tr><tr><td>*Young et al., 2010</td><td>Mental > physical sentences</td></tr><tr><td>*Zaitchik et al., 2010</td><td>Belief sentences > control sentences</td></tr></table> |
be693d037d5728952e751e13b54dd2c0a5e1b8b2bafd1a39f86113577f51fa39.png | complex | <table><tr><td></td><td colspan="2">With seizures<sup>§</sup></td><td></td><td rowspan="2">Without seizures</td></tr><tr><td></td><td>Early seizures</td><td>Late seizures</td><td><i>p</i>value</td></tr><tr><td></td><td>n = 13 (%)</td><td>n = 15 (%)</td><td></td><td>n = 152 (%)</td></tr><tr><td>Mean age, years</td>... | <table><tr><td></td><td colspan="2">With seizures§</td><td></td><td rowspan="2">Without seizures</td></tr><tr><td></td><td>Early seizures</td><td>Late seizures</td><td>pvalue</td></tr><tr><td></td><td>n = 13 (%)</td><td>n = 15 (%)</td><td></td><td>n = 152 (%)</td></tr><tr><td>Mean age, years</td><td>47.3 ± 17.3</td><td... | <table><tr><td>urbance</td><td>.3)</td><td></td><td></td><td>)</td></tr><tr><td>Hearing impairment</td><td>1 (7.6)</td><td>1 (6.6)</td><td>1.0</td><td>4 (2.6)</td></tr><tr><td>Hyponatremia</td><td>3 (23.1)</td><td>2 (13.3)</td><td>0.64</td><td>21 (13.8)</td></tr><tr><td>Outcome</td><td></td><td></td><td></td><td></td><... |
1f5f3846e2a14069c1532f4d685538471eb0babafe5d5bdfaf4330777fbf9caf.png | complex | <table><tr><td>Scale</td><td>Whole sample</td><td colspan="3">Gender</td><td colspan="3">Presence of symptoms</td></tr><tr><td></td><td>N = 446</td><td>Boys N = 207</td><td>Girls N = 239</td><td>p-value (ANOVA)</td><td>No symptoms N = 197</td><td>At least one symptom once a week N = 199</td><td>p-value (ANOVA)</td></tr... | <table><tr><td>Scale</td><td>Whole sample</td><td colspan="3">Gender</td><td colspan="3">Presence of symptoms</td></tr><tr><td></td><td>N = 446</td><td>Boys N = 207</td><td>Girls N = 239</td><td>p-value (ANOVA)</td><td>No symptoms N = 197</td><td>At least one symptom once a week N = 199</td><td>p-value (ANOVA)</td></tr... | <table><tr><td>Scale</td><td>Whole sample</td><td colspan="3">Gender</td><td colspan="3">Presence of symptoms</td></tr><tr><td>RF</td><td>61.4 ± 20.7</td><td>54.9 ± 18.8</td><td>67.0 ± 20.8</td><td>p < 0.001</td><td>61.2 ± 20.7</td><td>62.8 ± 20.9</td><td>0.4</td></tr><tr><td>RP</td><td>53.0 ± 26.2</td><td>55.4 ± 24.9<... |
0e888c0c3a134a6d66cf0fae547c4e6c4746c4858a0da3c82e1efddd086dba72.png | complex | <table><tr><td rowspan="2">Maternal health service use indicator</td><td rowspan="2">Overall (<i>n</i> = 1457)</td><td colspan="2">District</td><td rowspan="2"><i>P</i> value</td></tr><tr><td>Jhelum (<i>n</i> = 747)</td><td>Layyah (<i>n</i> = 710)</td></tr><tr><td>Sought at least one antenatal care (ANC) visit</td><td>... | <table><tr><td rowspan="2">Maternal health service use indicator</td><td rowspan="2">Overall (n = 1457)</td><td colspan="2">District</td><td rowspan="2">P value</td></tr><tr><td>Jhelum (n = 747)</td><td>Layyah (n = 710)</td></tr><tr><td>Sought at least one antenatal care (ANC) visit</td><td>96.6</td><td>97.8</td><td>95... | <table><tr><td>Type of ANC provider</td><td></td><td></td><td></td><td></td></tr><tr><td>Community Midwife (CMW)</td><td>8.3</td><td>13.8</td><td>2.4</td><td>0.00</td></tr><tr><td>Doctor</td><td>57.5</td><td>57.2</td><td>57.8</td><td>0.83</td></tr><tr><td>Skilled birth attendant</td><td>27.2</td><td>24.3</td><td>30.4</... |
c3e974bb607779f0afb2364ee61779faae83478577d625acbcd39e270a9edd14.png | complex | <table><tr><td></td><td>High-energy probe</td><td>Low-energy probe</td><td>Units</td></tr><tr><td>Source used</td><td><sup>22</sup>Na</td><td><sup>99m</sup>Tc</td><td></td></tr><tr><td>Photon energy</td><td>511</td><td>142</td><td>keV</td></tr><tr><td>Sensitivity</td><td>10</td><td>12</td><td>cps/kBq</td></tr><tr><td c... | <table><tr><td></td><td>High-energy probe</td><td>Low-energy probe</td><td>Units</td></tr><tr><td>Source used</td><td>22Na</td><td>99mTc</td><td></td></tr><tr><td>Photon energy</td><td>511</td><td>142</td><td>keV</td></tr><tr><td>Sensitivity</td><td>10</td><td>12</td><td>cps/kBq</td></tr><tr><td colspan="4">Spatial res... | <table><tr><td></td><td>High-energy probe</td><td>Low-energy probe</td><td>Units</td></tr><tr><td>Shielding</td><td>n.a.</td><td>1</td><td>mmPb</td></tr><tr><td>Weight</td><td>500</td><td>650</td><td>g</td></tr></table> |
0efed21407dc158d6bacdffaf89c5d686bf718d59d8541202955ae59566ae7e7.png | simple | <table><tr><td>Data</td><td>Feature</td><td>Vector</td><td>Algorithm</td><td>F1</td><td>AUC</td><td><i>p</i>-value</td></tr><tr><td>iDASH</td><td>Bag-of-words + UMLS (5SG)</td><td>Tf-idf</td><td>SVM-Lin</td><td>0.932</td><td>0.957</td><td><0.01</td></tr><tr><td></td><td>Bag-of-words + UMLS (All)</td><td>Tf-idf</td><... | <table><tr><td>Data</td><td>Feature</td><td>Vector</td></tr><tr><td>iDASH</td><td>Bag-of-words + UMLS (5SG)</td><td>Tf-idf</td></tr><tr><td></td><td>Bag-of-words + UMLS (All)</td><td>Tf-idf</td></tr><tr><td></td><td>Bag-of-words + UMLS (15ST)</td><td>Tf-idf</td></tr><tr><td></td><td>Bag-of-words + UMLS (All)</td><td>Tf... | <table><tr><td>Algorithm</td><td>F1</td><td>AUC</td><td>p-value</td></tr><tr><td>SVM-Lin</td><td>0.932</td><td>0.957</td><td><0.01</td></tr><tr><td>SVM-Lin</td><td>0.931</td><td>0.957</td><td><0.01</td></tr><tr><td>SVM-Lin</td><td>0.930</td><td>0.957</td><td><0.01</td></tr><tr><td>SVM-Lin-SGD</td><td>0.928</td><td>0.95... |
5e50bc49272936126da507bd36c013e5598e511b1fb8409f05bda246871a8094.png | simple | <table><tr><td>Characteristic</td><td>Number (N = 1,568)</td><td>Percent (%)</td></tr><tr><td>Sex</td><td>915</td><td>58.4</td></tr><tr><td>Female</td><td>653</td><td>41.6</td></tr><tr><td>Male</td><td></td><td></td></tr><tr><td>Age group (in years)</td><td></td><td></td></tr><tr><td>15 – 24</td><td>410</td><td>2... | <table><tr><td>Characteristic</td><td>Number (N = 1,568)</td><td>Percent (%)</td></tr><tr><td>Sex</td><td>915</td><td>58.4</td></tr><tr><td>Female</td><td>653</td><td>41.6</td></tr><tr><td>Male</td><td></td><td></td></tr><tr><td>Age group (in years)</td><td></td><td></td></tr><tr><td>15 – 24</td><td>410</td><td>26.1</t... | <table><tr><td>abiting</td><td>9</td><td></td></tr><tr><td>Single</td><td>444</td><td>27.7</td></tr><tr><td>Divorced/separated/widowed</td><td>155</td><td>10.1</td></tr><tr><td>Occupation</td><td></td><td></td></tr><tr><td>Student</td><td>56</td><td>3.6</td></tr><tr><td>Salaried employed</td><td>36</td><td>2.3</td></tr... |
8a318e331bf48e4ad384729ef1c099fbd6a49adca7d9c91fe703a82d7bebce58.png | simple | <table><tr><td></td><td>CHF absent (n = 66)</td><td>CHF present (n = 29)</td><td>p</td></tr><tr><td>Age (years)</td><td>54.9 ± 10.2</td><td>65.8 ± 14.2</td><td>< 0.001</td></tr><tr><td>Systemic Hypertension</td><td>32 (49%)</td><td>18 (62%)</td><td>0.22</td></tr><tr><td>Diabetes Mellitus</td><td>12 (18%)</... | <table><tr><td></td><td>CHF absent (n = 66)</td><td>CHF present (n = 29)</td><td>p</td></tr><tr><td>Age (years)</td><td>54.9 ± 10.2</td><td>65.8 ± 14.2</td><td>< 0.001</td></tr><tr><td>Systemic Hypertension</td><td>32 (49%)</td><td>18 (62%)</td><td>0.22</td></tr><tr><td>Diabetes Mellitus</td><td>12 (18%)</td><td>5 (17%... | <table><tr><td>CKMB peak (iu/l)</td><td>205 ± 138</td><td>346 ± 239</td><td>0.004</td></tr><tr><td>Angiography</td><td></td><td></td><td></td></tr><tr><td>Non obstructive</td><td>5 (8%)</td><td>1 (3%)</td><td></td></tr><tr><td>One vessel disease</td><td>34 (51%)</td><td>10 (35%)</td><td></td></tr><tr><td>Multivessel di... |
382d0f83cddca8d51367bea9320581212c4de242a27d726968f292b97fcd5fa7.png | complex | <table><tr><td></td><td colspan="2">No. of children</td><td>Cumulative incidence</td></tr><tr><td>Year</td><td>Born alive</td><td>With clubfoot</td><td>per thousand (95% CI)</td></tr><tr><td>1991</td><td>62,189</td><td>70</td><td>1.12 (0.9–1.3)</td></tr><tr><td>1992</td><td>68,996</td><td>64</td><td>0.93 (0.8R... | <table><tr><td></td><td colspan="2">No. of children</td><td>Cumulative incidence</td></tr><tr><td>Year</td><td>Born alive</td><td>With clubfoot</td><td>per thousand (95% CI)</td></tr><tr><td>1991</td><td>62,189</td><td>70</td><td>1.12 (0.9–1.3)</td></tr><tr><td>1992</td><td>68,996</td><td>64</td><td>0.93 (0.8–1.2)</td>... | <table><tr><td></td><td colspan="2">No. of children</td><td>Cumulative incidence</td></tr><tr><td>Year</td><td>Born alive</td><td>With clubfoot</td><td>per thousand (95% CI)</td></tr><tr><td>1999</td><td>54,879</td><td>58</td><td>1.05 (0.9–1.2)</td></tr><tr><td>2000</td><td>53,152</td><td>63</td><td>1.19 (1.0–1.3)</td>... |
1f6fcff36fc7c307f8b2dbac5250fd8470136387a2ceb8edfb8b7c840de8d2a7.png | complex | <table><tr><td colspan="4">Group session topics</td></tr><tr><td>Session #</td><td>Physical activity</td><td>Nutrition</td><td>Educational incentive</td></tr><tr><td>1</td><td>Overview of healthy nutrition</td><td>Overview of exercise</td><td>Pedometer</td></tr><tr><td>2</td><td>Eating healthy on a budget</td><td>Being... | <table><tr><td colspan="4">Group session topics</td></tr><tr><td>Session #</td><td>Physical activity</td><td>Nutrition</td><td>Educational incentive</td></tr><tr><td>1</td><td>Overview of healthy nutrition</td><td>Overview of exercise</td><td>Pedometer</td></tr><tr><td>2</td><td>Eating healthy on a budget</td><td>Being... | <table><tr><td colspan="4">Identify support network of friends and family members for exercise</td></tr><tr><td colspan="4">Identify exercise locations in and around home</td></tr><tr><td colspan="4">Select physical activity goal</td></tr><tr><td colspan="4">Identify new physical activities to try</td></tr><tr><td cols... |
215591d858d895cb393c51918d08f39927cdb042eccfca7e42da767f53131aa2.png | simple | <table><tr><td>Feature</td><td><i>P. fici</i></td></tr><tr><td>Assembly size (Mb)</td><td>52</td></tr><tr><td>Scaffold N50 (Mb)</td><td>4</td></tr><tr><td>Coverage (fold)</td><td>24.5</td></tr><tr><td>GC content (%)</td><td>48.73</td></tr><tr><td>GC exon (%)</td><td>53.56</td></tr><tr><td>GC intron (%)</td><td>44.18</t... | <table><tr><td>Feature</td><td>P. fici</td></tr><tr><td>Assembly size (Mb)</td><td>52</td></tr><tr><td>Scaffold N50 (Mb)</td><td>4</td></tr><tr><td>Coverage (fold)</td><td>24.5</td></tr><tr><td>GC content (%)</td><td>48.73</td></tr><tr><td>GC exon (%)</td><td>53.56</td></tr><tr><td>GC intron (%)</td><td>44.18</td></tr>... | <table><tr><td>Gene density (genes per Mb)</td><td>296.9</td></tr><tr><td>Exons per gene</td><td>2.76</td></tr><tr><td>tRNA genes</td><td>258</td></tr><tr><td>rRNA genes</td><td>52</td></tr><tr><td>Pseudogenes</td><td>494</td></tr><tr><td>Transposable elements (%)</td><td>1.54</td></tr></table> |
eabdc044914cfe983f9c954720c16bca7f7f6b63b311d69ba81b953f7e950fd7.png | simple | <table><tr><td></td><td>Controls (<i>N</i> = 39) (%)</td><td>Cases (<i>N</i> = 123) %</td></tr><tr><td>Stage I</td><td>22 (56)</td><td>55 (45)</td></tr><tr><td>Stage II</td><td>14 (36)</td><td>54 (44)</td></tr><tr><td>Stage III</td><td>3 (8)</td><td>14 (11)</td></tr><tr><td>ER or PR positive/HER2 negative</td><td>33 (8... | <table><tr><td></td><td>Controls (N = 39) (%)</td><td>Cases (N = 123) %</td></tr><tr><td>Stage I</td><td>22 (56)</td><td>55 (45)</td></tr><tr><td>Stage II</td><td>14 (36)</td><td>54 (44)</td></tr><tr><td>Stage III</td><td>3 (8)</td><td>14 (11)</td></tr><tr><td>ER or PR positive/HER2 negative</td><td>33 (85)</td><td>104... | <table><tr><td></td><td>Controls (N = 39) (%)</td><td>Cases (N = 123) %</td></tr><tr><td>ER or PR positive/HER2 positive</td><td>6 (15)</td><td>19 (15)</td></tr></table> |
df6ed866700eb51da72a81a4283cc6462915686e607fb619c7089e337ded4ce5.png | simple | <table><tr><td>Mutation model</td><td>Sign test</td><td>Standardized differences test</td><td>Wilcoxon test</td></tr><tr><td>IAM</td><td>Hee = 20.49</td><td>T<sub>2 </sub>= 13.196</td><td>P (one tail for H deficiency) 1.000</td></tr><tr><td></td><td>Hd = 0</td><td>P = 0.000</td><td>P (one tail for H excess) 0.000</td><... | <table><tr><td>Mutation model</td><td>Sign test</td><td>Standardized differences test</td><td>Wilcoxon test</td></tr><tr><td>IAM</td><td>Hee = 20.49</td><td>T2 = 13.196</td><td>P (one tail for H deficiency) 1.000</td></tr><tr><td></td><td>Hd = 0</td><td>P = 0.000</td><td>P (one tail for H excess) 0.000</td></tr><tr><td... | <table><tr><td>Mutation model</td><td>Sign test</td><td>Standardized differences test</td><td>Wilcoxon test</td></tr><tr><td></td><td>P = 0.000</td><td></td><td></td></tr><tr><td>SMM</td><td>Hee = 22.40</td><td>T2 = 11.518</td><td>P (one tail for H deficiency) 1.000</td></tr><tr><td></td><td>Hd = 0</td><td>P = 0.000</t... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.